amitriptyline and Depression, Endogenous studies

Amitriptyline: Tricyclic antidepressant with anticholinergic and sedative properties. It appears to prevent the re-uptake of norepinephrine and serotonin at nerve terminals, thus potentiating the action of these neurotransmitters. Amitriptyline also appears to antagonize cholinergic and alpha-1 adrenergic responses to bioactive amines.
amitriptyline : An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(dimethylamino)propylidene group at position 5.

Research Excerpts

Excerpt	Relevance	Reference
"As described elsewhere the oral administration of 5 mg of the 5-HT3-receptor-antagonist Tropisetron in fibromyalgia exhibited less amelioration of pain in patients with a depression in comparison to patients without depression."	9.10	[The influence of depression on the effect of Tropisetron in the therapy of fibromyalgia]. ( Müller, W; Stratz, T; Varga, B, 2003)
"In this double-blind, non-placebo controlled study [corrected], 179 patients with treated breast cancer who fulfilled the ICD-10 criteria for an acute depressive episode underwent an 8-week course of antidepressant treatment with either the tricyclic amitriptyline (75-150 mg, n = 87) or the serotonin-reuptake inhibitor paroxetine (20-40 mg, n = 88)."	9.09	[A double-blind comparative study of the effectiveness and tolerance of paroxetine and amitriptyline in treatment of breast cancer patients with clinically assessed depression]. ( Contu, A; Gutschow, K; Möslinger-Gehmayr, R; Oberhoff, C; Schindler, AE; Staab, HJ; Zaninelli, R, 2000)
"Three hundred in- and outpatients suffering from depressive disorder, as diagnosed using DSM-III criteria were treated for 6 weeks under double-blind conditions in a multicenter controlled study of tianeptine vs."	9.07	The efficacy and safety of tianeptine in the treatment of depressive disorder: results of a controlled double-blind multicentre study vs. amitriptyline. ( Aguglia, E; Bertolino, A; Casacchia, M; Ciani, N; Invernizzi, G; Marchesi, GF; Nardini, M; Rapisarda, V, 1994)
"The study describes a sequential analysis of depression-related physical symptoms and their relationship to imipramine and amitriptyline plasma levels over 4 weeks of treatment in 79 unipolar and bipolar patients hospitalized for major depressive disorder."	9.07	The pattern of physical symptom changes in major depressive disorder following treatment with amitriptyline or imipramine. ( Bowden, CL; Casper, RC; Davis, JM; Hanin, I; Katz, MM; Koslow, SH, 1994)
"After 1 week of a single-blind placebo period, and prior to being randomly assigned to receive treatment with either fluoxetine or amitriptyline, patients meeting strict criteria for a diagnosis of major depressive disorder were given an auditory verbal learning test of working memory, and a blood sample was drawn."	9.07	Verbal learning by major depressive disorder patients during treatment with fluoxetine or amitriptyline. ( Blackshaw, SL; Bowen, RC; Cebrian-Perez, S; Dayal, N; Keegan, DL; Richardson, JS; Saleh, S; Shrikhande, S, 1994)
"In a double-blind, crossover study, the effects of 75 mg amitriptyline alone during 5 weeks on pain intensity were compared with the effects of a combination of 75 mg amitriptyline and 3 mg flupentixol during 5 weeks in 34 patients with somatoform pain disorder."	9.07	Does addition of low-dose flupentixol enhance the analgetic effects of low-dose amitriptyline in somatoform pain disorder? ( Edelbroek, PM; Linssen, ACG; Van Kempen, GMJ; Zitman, FG, 1991)
"Patients (n = 150) were randomized to a 6-week, double-blind study to evaluate the relative efficacy and safety of mirtazapine, amitriptyline, and placebo in the treatment of major depressive disorder symptoms."	9.06	Mirtazapine vs. amitriptyline vs. placebo in the treatment of major depressive disorder. ( Gilvary, E; Glaudin, V; Panagides, J; Smith, WT, 1990)
"We performed a randomized, double-blind clinical trial comparing the efficacy and safety of zimelidine with amitriptyline and placebo in outpatients with major depression, in particular patients with mixed anxiety/depressive symptomatology."	9.06	A double-blind comparative trial of zimelidine, amitriptyline, and placebo in patients with mixed anxiety and depression. ( Amsterdam, JD; Case, WG; Csanalosi, E; Rickels, K; Singer, M, 1986)
"Fluoxetine, a specific serotonin reuptake inhibitor, was compared to amitriptyline in the treatment of 51 outpatients with primary major depressive disorder."	9.05	A double-blind controlled clinical trial of fluoxetine and amitriptyline in the treatment of outpatients with major depressive disorder. ( Chouinard, G, 1985)
"The efficacy and safety of fluoxetine, a new antidepressant agent, were assessed in a double-blind, parallel, randomized study of 44 outpatients with major depressive disorder."	9.05	A comparative trial of fluoxetine and amitriptyline in patients with major depressive disorder. ( Feighner, JP, 1985)
"Tianeptine is a new tricyclic antidepressant."	7.77	[Therapeutic effects of tianeptine in patients with depression and anxiety disorders with or without associated alcoholism]. ( Delalleau, B; Ganry, H; Kamoun, A; Marey, C, 1991)
" We recently encountered a case of reversible amitriptyline-induced external ophthalmoplegia, which was first described by Mladinich and Carlow in 1977."	7.71	[External ophthalmoplegia caused by amitriptyline poisoning]. ( Pfefferkorn, T; Strupp, M; von Stuckrad-Barre, S; Wekerle, G, 2002)
"The specific binding of tritiated (3H)-clonidine, an alpha 2-adrenergic receptor agonist, to platelet membranes was measured in normal subjects and in patients with major depressive disorder."	7.66	Platelet alpha 2-adrenergic receptors in major depressive disorder. Binding of tritiated clonidine before and after tricyclic antidepressant drug treatment. ( García-Sevilla, JA; Greden, JF; Hollingsworth, PJ; Smith, CB; Zis, AP, 1981)
"A case is described of ventricular arrhythmias associated with doxepin and amitriptyline treatment in a patient with preexisting heart disease."	7.66	Ventricular arrhythmias induced by doxepin and amitriptyline: case report. ( Faber, R; Todd, RD, 1983)
"Four cases of hypnagogic or hypnopompic visual hallucinations in patients during amitriptyline treatment are reported."	7.66	Hypnagogic and hypnopompic hallucinations during amitriptyline treatment. ( Hemmingsen, R; Rafaelsen, OJ, 1980)
"Mirtazapine was tolerated better than amitriptyline treatment."	6.73	Effectiveness and tolerability of mirtazapine and amitriptyline in alcoholic patients with co-morbid depressive disorder: a randomized, double-blind study. ( Akdeniz, F; Altintoprak, AE; Coskunol, H; Kitapcioglu, G; Zorlu, N, 2008)
"Moclobemide appears to be a well tolerated antidepressant without the liability to produce significant postural hypotension and without the need for a tyramine-poor diet."	6.67	A double blind trial of moclobemide versus amitriptyline in the treatment of depressive disorders. ( Fraser, AR; Menkes, DB; Mullen, PE; Newburn, GM, 1990)
"Fengabine is a new GABAmimetic compound active in animal models predictive of antidepressant activity."	6.66	Fengabine, a new GABAmimetic agent in the treatment of depressive disorders: an overview of six double-blind studies versus tricyclics. ( Garreau, M; Magni, G; Orofiamma, B; Palminteri, R, 1989)
" Dosage range was 75-300 mg/day for active medications."	6.65	A double-blind evaluation of zimelidine in comparison to placebo and amitriptyline in patients with major depressive disorder. ( Behrnetz, S; Bush, DF; Claghorn, J; Gershon, S; Goldstein, BJ; Huitfeldt, B, 1983)
"Pizotyline at two dosage levels or one dosage level of amitriptyline were administered under double-blind conditions to 100 depressed out-patients in a community mental health clinic; 73 patients completed the four-week study."	6.64	Clinical results with pizotyline in depression. ( Calobrisi, A; Olgiati, S, 1974)
" While under amitriptyline 75 mg/day no adverse effects were observed, immediately after increasing the dosage to 150 mg/day "head spasms" with headache, profuse sweating and arterial hypertension appeared."	5.30	[Unmasking pheochromocytoma by amitriptyline]. ( Kuhs, H, 1998)
"This report describes a case of encephalopathy developed in the course of amitriptyline therapy, during a remission of unipolar depression."	5.29	Encephalopathy during amitriptyline therapy: are neuroleptic malignant syndrome and serotonin syndrome spectrum disorders? ( Kamijima, K; Miyaoka, H, 1995)
"Fifty Caucasian inpatients with at least medium-grade depressive disorder received amitriptyline at a fixed dose of 75 mg twice a day."	5.11	Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy. ( Bachofer, J; Kissling, W; Leucht, S; Messner, B; Pfeiffer, H; Popp, J; Steimer, W; von Amelunxen, S; Zöpf, K, 2005)
"As described elsewhere the oral administration of 5 mg of the 5-HT3-receptor-antagonist Tropisetron in fibromyalgia exhibited less amelioration of pain in patients with a depression in comparison to patients without depression."	5.10	[The influence of depression on the effect of Tropisetron in the therapy of fibromyalgia]. ( Müller, W; Stratz, T; Varga, B, 2003)
"In this double-blind, non-placebo controlled study [corrected], 179 patients with treated breast cancer who fulfilled the ICD-10 criteria for an acute depressive episode underwent an 8-week course of antidepressant treatment with either the tricyclic amitriptyline (75-150 mg, n = 87) or the serotonin-reuptake inhibitor paroxetine (20-40 mg, n = 88)."	5.09	[A double-blind comparative study of the effectiveness and tolerance of paroxetine and amitriptyline in treatment of breast cancer patients with clinically assessed depression]. ( Contu, A; Gutschow, K; Möslinger-Gehmayr, R; Oberhoff, C; Schindler, AE; Staab, HJ; Zaninelli, R, 2000)
"To determine amitriptyline's (AMI) efficacy in the acute treatment of adolescent major depressive disorder (MDD)."	5.08	A randomized, controlled trial of amitriptyline in the acute treatment of adolescent major depression. ( Birmaher, B; Dachille, S; Iyengar, S; Kye, CH; Ryan, ND; Waterman, GS; Williamson, DE, 1996)
" Efficacy, compliance and its determinants were investigated in 66 patients suffering from major depressive disorder and treated in a double-blind manner with fluoxetine 20 mg/day or amitriptyline 150 mg/day for 9 weeks."	5.08	Compliance in depressed patients treated with fluoxetine or amitriptyline. Belgian Compliance Study Group. ( Demyttenaere, K; Gaens, E; Gregoire, J; Mesters, P; Van Ganse, E, 1998)
"Three hundred in- and outpatients suffering from depressive disorder, as diagnosed using DSM-III criteria were treated for 6 weeks under double-blind conditions in a multicenter controlled study of tianeptine vs."	5.07	The efficacy and safety of tianeptine in the treatment of depressive disorder: results of a controlled double-blind multicentre study vs. amitriptyline. ( Aguglia, E; Bertolino, A; Casacchia, M; Ciani, N; Invernizzi, G; Marchesi, GF; Nardini, M; Rapisarda, V, 1994)
"The study describes a sequential analysis of depression-related physical symptoms and their relationship to imipramine and amitriptyline plasma levels over 4 weeks of treatment in 79 unipolar and bipolar patients hospitalized for major depressive disorder."	5.07	The pattern of physical symptom changes in major depressive disorder following treatment with amitriptyline or imipramine. ( Bowden, CL; Casper, RC; Davis, JM; Hanin, I; Katz, MM; Koslow, SH, 1994)
"After 1 week of a single-blind placebo period, and prior to being randomly assigned to receive treatment with either fluoxetine or amitriptyline, patients meeting strict criteria for a diagnosis of major depressive disorder were given an auditory verbal learning test of working memory, and a blood sample was drawn."	5.07	Verbal learning by major depressive disorder patients during treatment with fluoxetine or amitriptyline. ( Blackshaw, SL; Bowen, RC; Cebrian-Perez, S; Dayal, N; Keegan, DL; Richardson, JS; Saleh, S; Shrikhande, S, 1994)
"Fluoxetine, a serotonin uptake inhibitor, and amitriptyline, a tricyclic antidepressant, were compared in a 5-week, multicenter, double-blind, randomized trial in 136 out-patient men and women, aged 21-70 years, with major depressive disorder."	5.07	Fluoxetine versus amitriptyline in the treatment of major depression: a multicenter trial. ( Beasley, CM; Potvin, JH; Sayler, ME, 1993)
"In a double-blind, crossover study, the effects of 75 mg amitriptyline alone during 5 weeks on pain intensity were compared with the effects of a combination of 75 mg amitriptyline and 3 mg flupentixol during 5 weeks in 34 patients with somatoform pain disorder."	5.07	Does addition of low-dose flupentixol enhance the analgetic effects of low-dose amitriptyline in somatoform pain disorder? ( Edelbroek, PM; Linssen, ACG; Van Kempen, GMJ; Zitman, FG, 1991)
"Patients (n = 150) were randomized to a 6-week, double-blind study to evaluate the relative efficacy and safety of mirtazapine, amitriptyline, and placebo in the treatment of major depressive disorder symptoms."	5.06	Mirtazapine vs. amitriptyline vs. placebo in the treatment of major depressive disorder. ( Gilvary, E; Glaudin, V; Panagides, J; Smith, WT, 1990)
"Forty-two outpatients with major depressive disorder entered a double-blind, randomized trial of either desipramine or amitriptyline for a minimum of 6 weeks."	5.06	Reduced REM latency predicts response to tricyclic medication in depressed outpatients. ( Debus, JR; Feldman-Koffler, F; Giles, DE; Jarrett, RB; Orsulak, PJ; Roffwarg, HP; Rush, AJ; Weissenburger, J, 1989)
"To establish the differential indication of trazodone and to find the predictors of its efficacy, we conducted a study in which 45 patients with major depressive disorder and 75 patients with acute schizophrenia were randomly assigned under double-blind conditions to either 400 mg trazodone daily, 150 mg amitriptyline daily, 20 mg haloperidol daily, or placebo daily."	5.06	Experimental examination of trazodone. ( Klieser, E; Lehmann, E, 1989)
"We performed a randomized, double-blind clinical trial comparing the efficacy and safety of zimelidine with amitriptyline and placebo in outpatients with major depression, in particular patients with mixed anxiety/depressive symptomatology."	5.06	A double-blind comparative trial of zimelidine, amitriptyline, and placebo in patients with mixed anxiety and depression. ( Amsterdam, JD; Case, WG; Csanalosi, E; Rickels, K; Singer, M, 1986)
"In a prospective, controlled, double-blind study, 37 patients with major depressive disorder were subclassified into primary depression (N = 25) and secondary (N = 12) depression and treated with either amitriptyline (primary depressives N = 13, secondary depressives N = 6) or bupropion (primary depressives N = 12, secondary depressives N = 6)."	5.06	Differential effect of amitriptyline and bupropion on primary and secondary depression: a pilot study. ( Mac, D; Othmer, E; Othmer, SC; Preskorn, SH, 1988)
"The author compared the response to amitriptyline in headache associated with depression between twelve patients having primary depression (control group) and ten patients with depression after minor closed head injury."	5.06	Antidepressants not effective in headache associated with minor closed head injury. ( Saran, A, 1988)
"Using a simple S1S2-R paradigm, acoustically evoked potentials, CNV, and PINV were recorded in 59 patients with major depressive disorder before and during a 4 week double blind pharmacological treatment with either amitriptyline (AT) or oxaprotiline (OT)."	5.06	[Changes in slow evoked potentials in depressed patients treated with amitriptyline and oxaprotiline]. ( Giedke, H; Heimann, H; Rein, W, 1987)
"A double-blind, randomized clinical study was conducted in thirty-four out-patients suffering from major depressive disorders comparing zimelidine with amitriptyline."	5.05	A double-blind comparison of zimelidine and amitriptyline in depressive out-patients. ( Lehtinen, V; Salminen, J; Syvälahti, E, 1982)
"Thirty-four patients who met Research Diagnostic Criteria for the diagnosis of major depressive disorder, primary subtype, were given the dexamethasone suppression test (DST) and a methylphenidate challenge."	5.05	Dexamethasone suppression test and mood response to methylphenidate in primary depression. ( Brawley, P; Brown, P, 1983)
"A double-blind multicenter evaluation compared the antidepressant efficacy of bupropion (Wellbutrin) to both placebo and amitriptyline (Elavil, Endep) in adult patients who met DSM-III criteria for major depressive disorder."	5.05	Antidepressant response and plasma concentrations of bupropion. ( Preskorn, SH, 1983)
"Fourteen out-patients with major depressive disorder completed a double-blind, randomized, parallel group study using trazodone (n = 6), amitriptyline (n = 5) and matching placebo (n = 3)."	5.05	Electrophysiological and haemodynamic changes with trazodone, amitriptyline and placebo in depressed out-patients. ( Ankier, SI; Silverstone, T; Van de Merwe, TJ, 1984)
"Amoxapine, a new antidepressant of the dibenzoxazepine class, was compared with amitriptyline in 80 patients with primary unipolar depressive disorders."	5.05	Amoxapine and amitriptyline: serum levels and clinical response in patients with primary unipolar depression. ( Click, MA; Zisook, S, 1982)
"Thirty newly hospitalized patients with RDC major or minor depressive disorder were randomly assigned to open treatment according to fixed dosage steps with 1) amitriptyline alone, up to a maximum dose of 300 mg/day; 2) tranylcypromine alone, up to a maximum dose of 40 mg/day; or 3) the combination of amitriptyline, up to 150 mg/day, and tranylcypromine, up to 20 mg/day."	5.05	Combined monoamine oxidase inhibitor-tricyclic antidepressant treatment: a pilot study. ( Boyd, JL; Pistole, T; White, K, 1980)
"Forty-two patients with depression and epilepsy were entered into an antidepressant trial of amitriptyline, nomifensine and placebo."	5.05	The treatment of depression in patients with epilepsy. A double-blind trial. ( Robertson, MM; Trimble, MR, 1985)
"Fluoxetine, a specific serotonin reuptake inhibitor, was compared to amitriptyline in the treatment of 51 outpatients with primary major depressive disorder."	5.05	A double-blind controlled clinical trial of fluoxetine and amitriptyline in the treatment of outpatients with major depressive disorder. ( Chouinard, G, 1985)
"The efficacy and safety of fluoxetine, a new antidepressant agent, were assessed in a double-blind, parallel, randomized study of 44 outpatients with major depressive disorder."	5.05	A comparative trial of fluoxetine and amitriptyline in patients with major depressive disorder. ( Feighner, JP, 1985)
"As part of a double-blind clinical trial comparing phenelzine and amitriptyline in outpatients with predominantly major depressive disorder, plasma tricyclic antidepressant drug concentrations were measured in 83 amitriptyline-treated patients."	5.05	Amitriptyline and hydroxylated metabolite plasma levels in depressed outpatients. ( Albright, D; Cooper, TB; Corcella, J; Howard, D; Robinson, DS, 1985)
"Amitriptyline and duloxetine are recommended in the case of comorbid depressive disorders or generalized anxiety disorder and pregabalin in the case of generalized anxiety disorder."	4.95	[Drug therapy of fibromyalgia syndrome : Updated guidelines 2017 and overview of systematic review articles]. ( Alten, R; Bär, KJ; Bernateck, M; Brückle, W; Friedel, E; Häuser, W; Henningsen, P; Petzke, F; Sommer, C; Tölle, T; Üçeyler, N; Winkelmann, A, 2017)
" Results of short term clinical trials have shown paroxetine to be significantly superior to placebo, and comparable to amitriptyline, clomipramine, imipramine, dothiepin and mianserin in relieving symptoms associated with major depressive disorders."	4.78	Paroxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. ( Clissold, SP; Dechant, KL, 1991)
"We describe a 55-year-old woman with extensive digestive resection and recurrent depressive disorder resistant to oral clomipramine tablets but not to an oral solution of amitriptyline."	3.77	Therapeutic drug monitoring of clomipramine and amitriptyline in a depressed patient with upper digestive tract resection. ( Allilaire, JF; Couturier, PL; Goldwirt, L; Lambrey, S; Warot, D; Zahr, N, 2011)
"Tianeptine is a new tricyclic antidepressant."	3.77	[Therapeutic effects of tianeptine in patients with depression and anxiety disorders with or without associated alcoholism]. ( Delalleau, B; Ganry, H; Kamoun, A; Marey, C, 1991)
" Chronic dosing produces down-regulation of beta-adrenergic receptors."	3.76	Sertraline: a new antidepressant. ( Caillard, V; Doogan, DP, 1988)
"They have definitive properties in neurotic depressions and mixed anxious-depressive states."	3.75	[Use of benzodiazepines in the treatment of depression]. ( Escande, M; Girard, M; Granier, F, 1983)
" We recently encountered a case of reversible amitriptyline-induced external ophthalmoplegia, which was first described by Mladinich and Carlow in 1977."	3.71	[External ophthalmoplegia caused by amitriptyline poisoning]. ( Pfefferkorn, T; Strupp, M; von Stuckrad-Barre, S; Wekerle, G, 2002)
" Chronic treatment with amitriptyline (AMI) further impaired 5-HT1A-mediated hypothermia."	3.68	5-HT1A receptor function in depression: effect of chronic amitriptyline treatment. ( Disselkamp-Tietze, J; Lesch, KP; Schmidtke, A, 1990)
" Seven patients who satisfied criteria for premenstrual syndrome (PMS) were treated successfully with amitriptyline."	3.68	Premenstrual syndrome in three generations responds to antidepressants. ( Taghavi, E, 1990)
"The specific binding of tritiated (3H)-clonidine, an alpha 2-adrenergic receptor agonist, to platelet membranes was measured in normal subjects and in patients with major depressive disorder."	3.66	Platelet alpha 2-adrenergic receptors in major depressive disorder. Binding of tritiated clonidine before and after tricyclic antidepressant drug treatment. ( García-Sevilla, JA; Greden, JF; Hollingsworth, PJ; Smith, CB; Zis, AP, 1981)
"A case is described of ventricular arrhythmias associated with doxepin and amitriptyline treatment in a patient with preexisting heart disease."	3.66	Ventricular arrhythmias induced by doxepin and amitriptyline: case report. ( Faber, R; Todd, RD, 1983)
"Somatic side effects of antidepressant medications and of depression and anxiety were quantified in depressed patients before and after 4 weeks of treatment with amitriptyline (N = 11), or desipramine (N = 12)."	3.66	Somatic symptoms in depression and antidepressants. ( Claghorn, JL; Mathew, RJ; Reck, JJ; Thapar, R; Weinman, ML, 1983)
"Monitoring tricyclic antidepressant concentrations in the plasma of 43 patients with major depressive disorders indicated that some responded to imipramine or desipramine but not to amitriptyline or nortriptyline, or vice versa, even though plasma levels were within therapeutic ranges."	3.66	The methylphenidate test for differentiating desipramine-responsive from nortriptyline-responsive depression. ( Bagri, S; Fawcett, J; Javaid, JI; Sabelli, HC, 1983)
"Four cases of hypnagogic or hypnopompic visual hallucinations in patients during amitriptyline treatment are reported."	3.66	Hypnagogic and hypnopompic hallucinations during amitriptyline treatment. ( Hemmingsen, R; Rafaelsen, OJ, 1980)
" Dosage was increased stepwise from 100mg up to 400mg trimipramine and from 100mg up to 200mg amitriptyline combined with 2mg up to 7."	2.74	Outcome in delusional depression comparing trimipramine monotherapy with a combination of amitriptyline and haloperidol--a double-blind multicenter trial. ( Ackl, N; Hatzinger, M; Held, K; Holsboer, F; Holsboer-Trachsler, E; Ising, M; Kaschka, W; Kasper, S; Konstantinidis, A; Künzel, HE; Sonntag, A; Steiger, A; Uhr, M; Yassouridis, A, 2009)
"Mirtazapine was tolerated better than amitriptyline treatment."	2.73	Effectiveness and tolerability of mirtazapine and amitriptyline in alcoholic patients with co-morbid depressive disorder: a randomized, double-blind study. ( Akdeniz, F; Altintoprak, AE; Coskunol, H; Kitapcioglu, G; Zorlu, N, 2008)
" Patients were treated with either amitriptyline (n = 69) or doxepin (n = 15); the mean dosage at endpoint was 126 +/- 35 mg and 155 +/- 47 mg, respectively."	2.71	Therapeutic drug monitoring of tricyclic antidepressants: how does it work under clinical conditions? ( Dragicevic, A; Fric, M; Gaertner, I; Grasmäder, K; Härtter, S; Hermann, E; Hiemke, C; Kuss, HJ; Laux, G; Müller, MJ; Oehl, W; Rao, ML; Rollmann, N; Weber-Labonte, M; Weigmann, H, 2003)
" In contrast, SR was diminished and the dilation phase of VR was prolonged following multiple dosing with amitriptyline (P < 0."	2.71	The effects of St. John's wort extract and amitriptyline on autonomic responses of blood vessels and sweat glands in healthy volunteers. ( Joraschky, P; Kirch, W; Krause, S; Mueck-Weymann, M; Siepmann, M, 2004)
"In a cross-over design, 44 patients with a major depressive episode (ICD-10) were randomly allocated to 4 weeks treatment with amitriptyline (150 mg/d) in combination with either late sleep deprivation (of the second half of the night, LSD) twice weekly during week 1 and 2 followed by LSDs once weekly during week 3 and 4 or vice versa."	2.69	Repeated sleep deprivation once versus twice a week in combination with amitriptyline. ( Kemper, B; Kuhs, H; Lippe-Neubauer, U; Meyer-Dunker, J; Tölle, R, 1998)
" A total of 123 patients (62 RIS; 61 HAL/AMI) were included; the mean daily dosage at endpoint was 6."	2.69	Risperidone versus haloperidol and amitriptyline in the treatment of patients with a combined psychotic and depressive syndrome. ( Benkert, O; Hillert, A; Müller, MJ; Müller-Siecheneder, F; Szegedi, A; Wetzel, H, 1998)
"Amitriptyline was better than placebo with fewer patients suffering a recurrence of symptoms, but there was no difference from placebo in the proportion of patients with sustained response."	2.69	Mirtazapine versus amitriptyline in the long-term treatment of depression: a double-blind placebo-controlled study. ( Montgomery, SA; Reimitz, PE; Zivkov, M, 1998)
"Amitriptyline was associated with more autonomic and circulatory side effects, while epigastric complaints occurred more often with sertraline."	2.69	Double-blind, multicenter comparative study of sertraline and amitriptyline in hospitalized patients with major depression. ( Arató, M; Bauer, H; Gallinat, J; Hegerl, U; Janka, Z; Möller, HJ; Pflug, B, 1998)
" Efficacy was assessed weekly with the 21-item Hamilton Rating Scale for Depression (HAM-D) and the Clinical Global Impression Scale (CGI), and safety was assessed with the Dosage Record and Treatment Emergent Symptom Scale."	2.69	Paroxetine and amitriptyline augmentation of lithium in the treatment of major depression: a double-blind study. ( Bauer, M; Meister, W; Müller-Oerlinghausen, B; Zaninelli, R, 1999)
"Fluoxetine was given at a fixed dose of 20 mg/day and amitriptyline was given in a range of 50-250 mg/day (mean of 138."	2.69	Fluoxetine versus amitriptyline in the treatment of major depression with associated anxiety (anxious depression): a double-blind comparison. ( Dávila, J; Mata, S; Mazzotti, G; Ontiveros, A; Ospina, J; Pacheco, A; Palacios, M; Plewes, J; Tamura, R; Versiani, M, 1999)
"The immediate antidepressive effect of sleep deprivation diminished in the course of the sleep deprivation series."	2.68	Amitriptyline in combination with repeated late sleep deprivation versus amitriptyline alone in major depression. A randomised study. ( Borgstädt, S; Färber, D; Kuhs, H; Mrosek, S; Tölle, R, 1996)
" Average dosage for amitriptyline was 98 +/- 37 mg/day, average lithium blood level was 0."	2.68	Comparative efficacy of lithium and amitriptyline in the maintenance treatment of recurrent unipolar depression: a randomised study. ( Czernik, A; Engel, RR; Erazo, N; Giedke, H; Greil, W; Ludwig-Mayerhofer, W; Müller-Oerlinghausen, B; Osterheider, M; Rudolf, GA; Sauer, H; Tegeler, J; Wetterling, T, 1996)
"Amitriptyline therapy was associated with significantly more treatment-related adverse events, and discontinuations due to treatment-related adverse events, in comparison to both sertraline and placebo therapy."	2.68	A double-blind, placebo-controlled study comparing the effects of sertraline versus amitriptyline in the treatment of major depression. ( Harrison, WM; Hertzman, M; Lydiard, RB; Stahl, SM, 1997)
"doxepine in the treatment of in-patients with severe depression."	2.67	A double-blind comparison of amitriptylinoxide versus doxepine in the treatment of severe depression. ( Diehl, B; Heinrich, T; König, W, 1994)
"The pharmacokinetic parameters and the time course of the effect after acute oral administration of yohimbine on salivary secretion in patients treated with tricyclic antidepressants were investigated."	2.67	Pharmacokinetic study of yohimbine and its pharmacodynamic effects on salivary secretion in patients treated with tricyclic antidepressants. ( Bagheri, H; Berlan, M; Houin, G; Montastruc, JL; Picault, P; Schmitt, L, 1994)
" Drug dosage was determined in a fixed-flexible design resulting in mean final doses of alprazolam 3."	2.67	Alprazolam and amitriptyline in the treatment of moderate depression. ( Browne, M; Lapierre, YD; Oyewumi, K; Sarantidis, D, 1994)
"Paroxetine is a new compound in the group of the selective serotonin-reuptake inhibitors."	2.67	Double-blind multicenter study of paroxetine and amitriptyline in depressed inpatients. ( Berzewski, H; Eckmann, F; Gonzalves, N; Kissling, W; Knorr, W; Magyar, I; Möller, HJ; Ressler, P; Rudolf, GA; Steinmeyer, EM, 1993)
"Those with endogenous depression improved more than those with neurotic depression, irrespective of treatment group."	2.67	The efficacy and tolerability of combined antidepressant treatment in different depressive subgroups. ( McKeon, P; O'Brien, S; O'Regan, M, 1993)
"Moclobemide is a well-tolerated medication at therapeutic doses; it is globally as effective as amitriptyline in the treatment of major depression."	2.67	A double-blind placebo-controlled comparison of moclobemide and amitriptyline in the treatment of depression. ( Alda, M; Bakish, D; Ellis, J; Lapierre, Y; Wiens, A, 1992)
"Moclobemide is a specific monoamine oxidase-A inhibitor which does not bind irreversibly to the enzyme, unlike the currently available MAOIs."	2.67	An Australian multicentre study of moclobemide versus amitriptyline in the treatment of depression. ( Adena, M; Evans, L; George, T; Johnson, G; Mitchell, P; O'Sullivan, B, 1992)
"Data on blood pressure was extracted from the findings of a 6-week double-blind study that was carried out to evaluate the efficacy and safety of prescribing tranylcypromine (TCP) singly and in combination with amitriptyline (AMI)."	2.67	Blood pressure effects of tranylcypromine when prescribed singly and in combination with amitriptyline. ( McKeon, P; O'Brien, S; O'Flaherty, A; O'Regan, M; Patel, R, 1992)
"In 79 patients with endogenous depressions (66 MDP and 13 circular schizophrenic patients) which received high doses of tricyclic antidepressants (amitriptyline in agitated forms and melipramine++ in inhibited ones) that remained ineffective for at least one month, hemosorption (HS; 39 patients) or ECT (40 patients) were randomly applied."	2.67	[Comparative effectiveness of detoxification hemosorption and electroconvulsive therapy in patients with endogenous depression resistant to tricyclic antidepressants]. ( Kosov, NE; Mosolov, SN, 1991)
"Sertraline was also found to be effective in patients with a high baseline anxiety score on the Hamilton Rating Scale for Depression."	2.67	Controlling acute episodes of depression. ( Lapierre, YD, 1991)
"Amitriptyline was found to act within seven days on the components of anxiety and on hostility in the responders, and on sleep disorder in all patients."	2.67	Identifying the specific clinical actions of amitriptyline: interrelationships of behaviour, affect and plasma levels in depression. ( Bowden, CL; Casper, RC; Frazer, A; Katz, MM; Kocsis, J; Koslow, SH; Maas, JW; Secunda, S, 1991)
"Moclobemide appears to be a well tolerated antidepressant without the liability to produce significant postural hypotension and without the need for a tyramine-poor diet."	2.67	A double blind trial of moclobemide versus amitriptyline in the treatment of depressive disorders. ( Fraser, AR; Menkes, DB; Mullen, PE; Newburn, GM, 1990)
"Milnacipran is a new potential antidepressant selected for its equipotent inhibition of noradrenaline and serotonin uptake and its lack of effect at any postsynaptic receptor."	2.67	Pooling two controlled comparisons of milnacipran (F2207) and amitriptyline in endogenous inpatients. A new approach in dose ranging studies. ( Ansseau, M; Serre, C; Sutet, P; von Frenckell, R, 1990)
"Moclobemide was compared with amitriptyline for antidepressant efficacy, safety and tolerance."	2.67	Moclobemide versus amitriptyline in the treatment of depression: two small double-blind multicentre studies in Belgium. ( Beckers, G; Berger, M; de Bleeker, E; Faidherbe, J; Hellstern, K; Jaunes, C; Sieben, G; Vereecken, A; Ward, J; Wolfrum, C, 1990)
"Sertraline was associated with a statistically lower frequency of somnolence, dry mouth, constipation, ataxia, and pain and a higher frequency of nausea, anorexia, diarrhea/loose stools, and insomnia; thus, anticholinergic effects were less common and gastrointestinal effects were more common with sertraline than with amitriptyline."	2.67	Double-blind, multicenter comparison of sertraline and amitriptyline in elderly depressed patients. ( Claghorn, JL; Cohn, CK; Cohn, JB; Dessain, EC; Fabre, LF; Itil, TM; Lautin, A; Mendels, J; Shrivastava, R, 1990)
"Amitriptyline was more effective in inducing full recovery."	2.67	Amoxapine versus amitriptyline for continuation therapy of depression. ( Frances, AJ; Kocsis, JH; Mann, JJ; Mason, BJ, 1990)
"Isocarboxazid was replaced by placebo, using double-blind procedure."	2.67	Efficacy of combined antidepressant therapy in resistant neurotic disorder. ( Murphy, S; Tyrer, P, 1990)
"Fengabine is a new GABAmimetic compound active in animal models predictive of antidepressant activity."	2.66	Fengabine, a new GABAmimetic agent in the treatment of depressive disorders: an overview of six double-blind studies versus tricyclics. ( Garreau, M; Magni, G; Orofiamma, B; Palminteri, R, 1989)
"5 mg flupenthixol tablet in the morning and a placebo capsule at night (25 patients) or a 25 mg sustained-release amitriptyline capsule at night and a placebo tablet in the morning (26 patients), but at the end of the first or second weeks the dosage could be doubled according to the assessed clinical need."	2.66	Primary care treatment of depression in the elderly: a double-blind, multi-centre study of flupenthixol ('Fluanxol') and sustained-release amitriptyline. ( Asskilt, O; Austad, SG; Fjellheim, J; Høstmaelingen, EA; Høstmaelingen, HJ; Kristiansen, PH; Ofsti, E; Olsen, TI; Skotte, T, 1989)
" Patients were treated in monotherapy for 42 days with a mean dosage of 3 tablets per day corresponding to 37."	2.66	Efficacy of tianeptine in anxious-depressed patients: results of a controlled multicenter trial versus amitriptyline. ( Dreyfus, JF; Guelfi, JD; Pichot, P, 1989)
"Weight gain was detected only in patients receiving amitryptiline."	2.66	Efficacy and tolerability of fluoxetine in the elderly: a double-blind study versus amitryptiline. ( Altamura, AC; Guercetti, G; Invernizzi, G; Percudani, M, 1989)
"Amitriptyline was found to be considerably superior to placebo after six weeks and significantly so as early as two weeks after the start of treatment."	2.66	Double-blind placebo-controlled trial of amitriptyline among depressed patients in general practice. ( Bhat, A; Freeling, P; Hollyman, JA; Paykel, ES; Sedgwick, P, 1988)
"Paroxetine is a new antidepressant drug with potent serotonin (5HT) uptake inhibitory properties."	2.66	Paroxetine in the treatment of depression--a randomized comparison with amitriptyline. ( Laursen, AL; le Fèvre Honoré, P; Mikkelsen, PL; Rasmussen, S, 1985)
"Amitriptyline was superior to placebo in probable and definite major depressions on the Research Diagnostic Criteria but not in minor depressions."	2.66	Are tricyclic antidepressants useful for mild depression? A placebo controlled trial. ( Freeling, P; Hollyman, JA; Paykel, ES, 1988)
"The amitriptyline-treated group had complaints of dry mouth and dizziness on standing; the fluoxetine-treated group of sleep disturbances, nausea, and headaches."	2.66	A controlled comparison of fluoxetine and amitriptyline in depressed out-patients. ( Coleman, A; Lader, MH; Young, JP, 1987)
" Following a 1-week washout period, patients randomly received one of the two drugs up to 100 mg twice daily on a fixed increment dosage schedule."	2.66	A comparative double-blind controlled study of trimipramine and amitriptyline in major depression: lack of correlation with 5-hydroxytryptamine reuptake blockade. ( Caille, G; Cournoyer, G; de Montigny, C; Elie, R; Langlois, R; le Morvan, P; Ouellette, J, 1987)
"Plasma drug concentrations and clinical response were measured in two groups of hospitalised depressed patients, who received amitriptyline or imipramine double-blind, in a dosage of 250 mg for four weeks."	2.66	Imipramine and amitriptyline plasma concentrations and clinical response in major depression. ( Bowden, C; Brunswick, D; Hanin, I; Kocsis, JH, 1986)
" After 6 weeks of treatment with a daily dosage of 600 mg femoxetine or 150 mg amitriptyline, no statistically significant differences between the 2 treatment groups were observed, either when using the HDS or the clinical global assessment scale."	2.66	Femoxetine and amitriptyline in general practice: a randomized double-blind group comparison. ( Jeppesen, K; Skrumsager, BK, 1986)
" Dosage range was 75-300 mg/day for active medications."	2.65	A double-blind evaluation of zimelidine in comparison to placebo and amitriptyline in patients with major depressive disorder. ( Behrnetz, S; Bush, DF; Claghorn, J; Gershon, S; Goldstein, BJ; Huitfeldt, B, 1983)
"Zimeldine tolerability was compared to amitriptyline and placebo in a large multicentre study performed at three clinical research units in the U."	2.65	Zimeldine tolerability in comparison to amitriptyline and placebo: findings from a multicentre trial. ( Claghorn, J; Gershon, S; Goldstein, BJ, 1983)
"Amitriptyline has a significant advantage in insomnia problems."	2.65	Comparison between zimeldine and amitriptyline of efficacy and adverse symptoms--a combined analysis of four British clinical trials in depression. ( Huitfeldt, B; Montgomery, SA, 1983)
"Sixty patients meeting DSM-III criteria for major depression were assigned randomly to double-blind treatment for four weeks according to fixed-dosage steps with (1) amitriptyline hydrochloride alone, up to a maximum dosage of 300 mg/day; (2) tranylcypromine alone, up to 40 mg/day; or (3) the combination of amitriptyline hydrochloride, up to 150 mg/day, and tranylcypromine, up to 20 mg/day."	2.65	The safety and efficacy of combined amitriptyline and tranylcypromine antidepressant treatment. A controlled trial. ( Palmer, R; Razani, J; Rebal, R; Simpson, G; Sloane, RB; White, J; White, KL, 1983)
" The dosage was 150 mg daily in both treatment groups."	2.65	Nomifensine and amitriptyline in the treatment of depression. A multi-centre double-blind comparison. ( Agren, H; Bjaring, B; Källström, B; Lund, M; Månsby, J; Peterson, LE; Roos, BE; Wistedt, B, 1983)
"Trazodone was less troublesome in respect of the persistent dry mouth and severe adverse psychiatric reactions which occurred with amitriptyline."	2.65	Trazodone. A comparative clinical and predictive study. ( Ankier, SI; Kerr, TA; McClelland, HA; Stephens, DA, 1984)
"Bupropion is a novel, structurally unique (single ring) compound, radically different from tricyclic antidepressants in its pharmacologic profile."	2.65	Long-term efficacy and safety of bupropion. ( Othmer, E; Othmer, SC; Stern, WC; Van Wyck Fleet, J, 1983)
" The signal detection recognition memory task detected an impairment in memory after chronic amitriptyline administration, as contrasted with an improvement in memory after chronic administration of clovoxamine."	2.65	Effects of two antidepressants on memory performance in depressed outpatients: a double-blind study. ( Gelenberg, AJ; Lamping, DL; Spring, B, 1984)
" The duration of treatment was 4 weeks and the dosage of both drugs ranged from 50 to 150 mg/day."	2.65	A double-blind clinical comparison between nomifensine and amitriptyline in the treatment of endogenous depressions. ( Ayuso Gutierez, JL; López-Ibor Aliño, JJ; Montejo Iglesias, ML; Ramons, JL, 1982)
" Dosage was adjusted based on plasma level with the aim of achieving a concentration of 60-180 ng/ml."	2.65	Amitriptyline and nortriptyline response profiles in unipolar depressed patients. ( Bowden, CL; Lehmann, LS; Redmond, FC; Stanton, BC, 1982)
" The side effect profile of each drug was clinically different from one another with a notable absence of anticholinergic side effects characteristic of the bupropion group."	2.65	A comparison of the safety and efficacy of bupropion HCL and amitriptyline hcl in depressed outpatients. ( Campos, PE; Miles, JE; Misri, S; Remick, RA; Van Wyck Fleet, J, 1982)
"Amitriptyline-treated patients showed increased heart rate, PR, QRS, and QTc intervals."	2.65	Electrocardiographic effects of tranylcypromine vs. amitriptyline. ( O'Leary, J; Palmer, R; Razani, J; Rebal, R; White, K, 1983)
"Trimipramine patients were more seriously ill on initial diagnosis and showed significantly more improvement at week 2 than amitriptyline patients and a trend toward fewer side effects."	2.65	A controlled comparison of trimipramine and amitriptyline. ( Kline, NS, 1982)
"Amoxapine, a tricyclic dibenzoxazepine is an antidepressant which in the dosage range of 150-300 mg/day is notable for its rapid onset of action."	2.65	Systematic studies with amoxapine, a new antidepressant. ( Ban, TA; Fujimori, M; Petrie, WM; Ragheb, M; Wilson, WH, 1982)
" dosing schedule can provide relief of insomnia and improve the quality of sleep (47,61)."	2.65	Treating the depressed elderly patient: the comparative behavioral pharmacology of mianserin and amitriptyline. ( Branconnier, RJ; Cole, JO; Ghazvinian, S; Rosenthal, S, 1982)
"Flupenthixol decanoate in low dose is a useful anti-depressant, but should be restricted to short courses of treatment, to patients refractory to other treatments, and to patients suspected of poor compliance."	2.65	A controlled comparison of flupenthixol decanoate injections and oral amitriptyline in depressed out-patients. ( John, G; Lader, MH; Tam, W; Young, JP, 1982)
"Trazodone was found to be significantly better than placebo on almost every rating scale, particularly on those items or factors related to depression and associated anxiety."	2.65	Trazodone in the treatment of neurotic depression. ( Finnerty, RJ; Goldberg, HL, 1980)
"Pizotyline at two dosage levels or one dosage level of amitriptyline were administered under double-blind conditions to 100 depressed out-patients in a community mental health clinic; 73 patients completed the four-week study."	2.64	Clinical results with pizotyline in depression. ( Calobrisi, A; Olgiati, S, 1974)
"Mirtazapine is a noradrenergic and specific serotonergic antidepressant, characterized by a unique pharmacologic profile, favorable pharmacokinetics, and proven efficacy and safety."	2.40	Mirtazapine: clinical advantages in the treatment of depression. ( Burrows, GD; Kremer, CM, 1997)
" The meta-analysis of adverse events shows that mirtazapine was better tolerated than amitriptyline, particularly with respect to anticholinergic and cardiac adverse events."	2.40	Meta-analysis of randomized, double-blind, placebo-controlled, efficacy and safety studies of mirtazapine versus amitriptyline in major depression. ( Hoff, W; Panagides, J; Reimitz, PE; Stahl, S; Zivkov, M, 1997)
"Mirtazapine-treated patients demonstrated a statistically significant (p < or = ."	2.40	A meta-analysis of eight randomized, double-blind, controlled clinical trials of mirtazapine for the treatment of patients with major depression and symptoms of anxiety. ( Barkin, RL; Fawcett, J, 1998)
" The relative safety of different antidepressants has been assessed by looking at answers to the questions: how safe is the drug in overdose; how dangerous are its side effects at therapeutic dose; and does it have any dangerous interactions with other drugs or substances? Based on current data it can be said with reasonable confidence that fluvoxamine, fluoxetine, paroxetine and moclobemide are "safe" antidepressants, and mianserin and trazodone are also "safe" but to a lesser extent (mainly because of hypnosedation)."	2.39	Safety of antidepressants. ( de Jonghe, F; Swinkels, JA, 1995)
"Sertraline was without effect on vital signs or electrocardiogram, and had no clinically relevant effects on laboratory values."	2.38	Toleration and safety of sertraline: experience worldwide. ( Doogan, DP, 1991)
" Severe toxicity usually occurs at supratherapeutic plasma levels and might be prevented by tailoring the dosage according to the individual's drug hydroxylating capacity."	2.37	Clinical pharmacology of antidepressant drugs: pharmacogenetics. ( Bertilsson, L; Sjöqvist, F, 1984)
"It is important to understand both the kinetic and the dynamic implications of dosing TCAs and BZs in the elderly, for whom these drugs are frequently prescribed."	2.37	Implications of dosing tricyclic antidepressants and benzodiazepines in geriatrics. ( Cutler, NR; Narang, PK, 1984)
" Plasma level determinations can never replace sound clinical judgment and dosage adjustment for individual patients."	2.36	The role of plasma concentrations in the use of tricyclic antidepressant drugs. ( Levine, RR, 1979)
"Sertraline was the most frequently prescribed in adolescents (2009: 22."	1.48	Trends and Patterns of Antidepressant Use in French Children and Adolescents From 2009 to 2016: A Population-Based Study in the French Health Insurance Database. ( Baricault, B; Lapeyre-Mestre, M; Montastruc, F; Montastruc, JL; Raynaud, JP; Revet, A, 2018)
" Chronic administration of amitriptyline reversed the despaired behavior induced by exposure to UCMS paradigm and, fully recovered pNF-H labeling to control values."	1.46	Effect of amitriptyline treatment on neurofilament-H protein in an experimental model of depression. ( Galeotti, N; Ghelardini, C; Sanna, MD, 2017)
"Amitriptyline is a commonly prescribed tricyclic antidepressant, which has been shown to impair mitochondrial function and increase oxidative stress in a variety of in vitro assays."	1.38	Oral treatment with amitriptyline induces coenzyme Q deficiency and oxidative stress in psychiatric patients. ( Alcocer-Gómez, E; Carmona-López, MI; Casas-Barquero, N; Cordero, MD; de Miguel, M; Garrido-Maraver, J; Moreno-Fernández, AM; Sánchez-Alcázar, JA, 2012)
" Follow through of antidepressant prescription dosing recommendations by the prescriber was low."	1.38	Feasibility of nurse-led antidepressant medication management of depression in an HIV clinic in Tanzania. ( Adams, JL; Almond, ML; Ringo, EJ; Shangali, WH; Sikkema, KJ, 2012)
"Amitriptyline was found in 12 (7."	1.35	Tricyclic antidepressants abuse, with or without benzodiazepines abuse, in former heroin addicts currently in methadone maintenance treatment (MMT). ( Adelson, M; Peles, E; Schreiber, S, 2008)
"Amitriptyline is a potent anticholinergics, rarely used as a drug of abuse."	1.33	Recreational amitriptyline abuse. ( Chodorowski, Z; Habrat, B; Sein Anand, J, 2005)
"Amitriptyline treatment is not less expensive nor more effective than citalopram or fluoxetine therapies."	1.31	Costs and outcomes of use of amitriptyline, citalopram and fluoxetine in major depression: exploratory study. ( Hanus, H; Hosák, L; Straka, L; Tůma, I, 2000)
" Multiple-dose comedication with LI160 led to a statistically significant decrease in the area under the plasma concentration-time curve within one dosing interval of amitriptyline by 22% ( p = 0."	1.31	Decreased plasma levels of amitriptyline and its metabolites on comedication with an extract from St. John's wort ( Hypericum perforatum ). ( Bauer, S; Brockmöller, J; Johne, A; Langheinrich, M; Roots, I; Schmider, J; Scholler, G; Stadelmann, AM; Störmer, E, 2002)
"Fluoxetine was characterised by predominance of a stimulating effect from the first days of treatment as well as by relatively late manifestation of very thymoleptic and tranquilizing impact (during 3-4 weeks)."	1.30	[A comparative clinical evaluation of the antidepressive activity of fluoxetine and fluvoxamine]. ( Lopukhov, IG, 1997)
" While under amitriptyline 75 mg/day no adverse effects were observed, immediately after increasing the dosage to 150 mg/day "head spasms" with headache, profuse sweating and arterial hypertension appeared."	1.30	[Unmasking pheochromocytoma by amitriptyline]. ( Kuhs, H, 1998)
"Treatment with amitriptyline reduced levels of corticotropin and corticosterone, increased glucocorticoid receptor mRNA concentrations and glucocorticoid binding capacity of several brain areas, and reversed behavioural changes."	1.30	Regulation of corticosteroid receptor gene expression in depression and antidepressant action. ( Barden, N, 1999)
"In the patients with reactive depression, no differences could be detected as compared with the control group."	1.29	Are affective disorders associated with alterations of heart rate variability? ( Kaschka, WP; Rechlin, T; Spitzer, A; Weis, M, 1994)
"Doctors' prescription and dosing behaviour was investigated using data from 9 clinical trials in 550 patients treated with psychotropics."	1.29	Correct titration of non-drugs and some other methodological issues. ( Beneke, M; Fritze, J; Rasmus, W; Rød, IS, 1994)
"This report describes a case of encephalopathy developed in the course of amitriptyline therapy, during a remission of unipolar depression."	1.29	Encephalopathy during amitriptyline therapy: are neuroleptic malignant syndrome and serotonin syndrome spectrum disorders? ( Kamijima, K; Miyaoka, H, 1995)
"In connection with findings from sleep deprivation research in animals and in healthy subjects, the results suggest that thyroid changes under PSD may be nonspecific and unrelated to antidepressive PSD effects."	1.29	Serum prolactin, growth hormone, total corticoids, thyroid hormones and thyrotropine during serial therapeutic sleep deprivation. ( Farber, D; Kuhs, H; Tolle, R, 1996)
" This upper limit is 350 micrograms/l; as compared with previous work, they consider amitriptyline levels from 150 to 350 350 micrograms/l safe and therapeutically effective."	1.28	[Side effects of amitriptyline in relation to its plasma levels]. ( Krpálek, P; Pidrman, V, 1992)
" In an effort to determine whether this discrepancy may be due to possible inappropriate dosing or use of trazodone for different patient subtypes, a retrospective chart review of 138 depressed inpatients treated with amitriptyline and of 42 depressed inpatients treated with trazodone was performed to compare their respective prescribing patterns."	1.28	A drug utilization review of prescribing patterns for trazodone versus amitriptyline. ( Brown, CS; Bryant, SG; Hokanson, JA, 1990)
"When three subjects with severe pretreatment weight loss were excluded, however, the remaining seven patients showed a significant increase in the prolactin response to L-tryptophan, consistent with other published studies."	1.28	Effect of amitriptyline on endocrine responses to intravenous L-tryptophan. ( Cowen, PJ; Gelder, MG; Grahame-Smith, DG; McCance, SL, 1990)
"31 inpatients suffering from endogenous depression were subjected to walking therapy three times at intervals of one week."	1.28	[Repeating antidepressive sleep deprivation therapy (partial sleep deprivation)]. ( Fischer, H; Telger, K; Tölle, R, 1990)
" Proper dosage is determined by the patient's age and metabolic capabilities, and patient education increases compliance."	1.28	Chronic depression. Issues in long-term management. ( Bacani-Oropilla, T; Lippmann, SB, 1989)
"In the neurotic depression group 23 patients were subclassified as Primary Minor Depression, and 52% of them showed non-suppressor response to DST."	1.27	Dexamethasone suppression test as a predictor of drug treatment response. ( Arató, M; Grof, P; Rihmer, Z; Szádóczky, E, 1984)
"Ninety five patients with unipolar depression who received lithium therapy for one year were also studied."	1.27	Classification of depression and response to antidepressive therapies. ( Abou-Saleh, MT; Coppen, A, 1983)
" These findings show that chronic administration of low-modest doses of tricyclic antidepressants frequently cause considerable weight gain and can significantly interfere with the ability to provide long-term maintenance therapy."	1.27	Weight gain. A side-effect of tricyclic antidepressants. ( Berken, GH; Stern, WC; Weinstein, DO, 1984)
"Twenty-one depressed patients participated in a study that assessed the predictability of amitriptyline (AT) dosage based on plasma drug concentrations after a single dose."	1.27	Single-dose single-point method in amitriptyline therapy. ( Khazanie, PG; Madakasira, S; Sato, TL, 1984)
" When DMI dosage was raised after an initial steady state had been reached, the rise in plasma DMI level was proportionately greater than the increase in dosage, suggesting saturation of DMI elimination pathways."	1.27	The nonlinear kinetics of desipramine and 2-hydroxydesipramine in plasma. ( Cooke, RG; Persad, E; Reed, KL; Stancer, HC; Warsh, JJ, 1984)
" Results in 60 patients treated with amitriptyline indicated that both groups were comparable with respect to overall dropout rate, side-effect attrition, dosage of amitriptyline received, and clinical response."	1.27	Symptomatic volunteers in depression research: a closer look. ( Bellack, AS; Hersen, M; Himmelhoch, JM; Last, CG; Thase, ME, 1984)
"In the treatment of endogenous depression REM sleep deprivation and imipramine have similar efficacy."	1.27	Evidence for REM sleep deprivation as the mechanism of action of antidepressant drugs. ( Vogel, GW, 1983)
"Riboflavin was added to the medication to check compliance."	1.27	Amitriptyline metabolism in relation to antidepressive effect. ( de Wolff, FA; Edelbroek, PM; Rooymans, HG; Schreuder, JN; Zitman, FG, 1984)
"Eight depressed children with cancer had a rapid clinical response to low doses of imipramine or amitriptyline."	1.27	Tricyclic antidepressants for children with cancer. ( Cangir, A; Choroszy, M; Kumor, K; Pfefferbaum-Levine, B; Roseberry, EA, 1983)
"Responders with bipolar depression had smaller reductions in MHPG levels than did responders with unipolar depression."	1.27	Effects of amitriptyline and imipramine on brain amine neurotransmitter metabolites in cerebrospinal fluid. ( Bowden, CL; Davis, JM; Hanin, I; Koslow, SH; Maas, JW; Robins, E, 1985)
"Amitriptyline was well tolerated when given to patients after or together with moclobemide."	1.27	Moclobemide, a new reversible MAO inhibitor--interaction with tyramine and tricyclic antidepressants in healthy volunteers and depressive patients. ( Eichler, HG; Fischbach, R; Gasic, S; Korn, A, 1986)
"Lithium carbonate (600 mg/day) was then resumed."	1.27	[Rapid response of a disorder to the addition of lithium carbonate: panic resistant to tricyclic antidepressants]. ( Cournoyer, J, 1986)
"Amitriptyline was preferred for agitated depressions, and imipramine was preferred for retarded depressions."	1.27	Who benefits from tricyclic antidepressants: a survey. ( Bale, P; Ban, TA; Brockett, C; Friedel, RO; Goldberg, SC; Hamer, RM; Stephens, V; Tilley, DH, 1988)
"The debrisoquine-test appears to be a useful clinical tool for detecting in patients a genetic deficiency in the hydroxylation of AT-type drugs."	1.27	Amitriptyline pharmacokinetics and clinical response: II. Metabolic polymorphism assessed by hydroxylation of debrisoquine and mephenytoin. ( Baumann, P; Jonzier-Perey, M; Koeb, L; Küpfer, A; Schöpf, J; Tinguely, D, 1986)
" The absence of correlation between clinical improvement and pharmacokinetic parameters is discussed for its possible significance."	1.27	Amitriptyline pharmacokinetics and clinical response: I. Free and total plasma amitriptyline and nortriptyline. ( Baumann, P; Jonzier-Perey, M; Koeb, L; Lê, PK; Schöpf, J; Tinguely, D, 1986)
" Regardless of the reason for use, nonpsychiatric physicians were found to use relatively low dosages, rarely plan or effect dosage increases, and rarely discontinue medication."	1.27	Antidepressant treatment of medical-surgical inpatients by nonpsychiatric physicians. ( Callies, AL; Popkin, MK, 1987)
"Forty-six patients with various forms of endogenous depression were treated by night sleep deprivation (NSD) which was used as the cardinal method of treatment."	1.27	[Sleep deprivation as a method of treating endogenous depression]. ( Fakturovich, AIa; Vovin, RIa, 1985)
"Treatment with amitriptyline for 3 weeks did not affect the median thyrotropin (thyroid-stimulating hormone; TSH) response to thyrotropin-releasing hormone (TRH) in recovered patients, whereas that in relapsed patients was significantly enhanced."	1.27	Effect of amitriptyline on the thyrotropin response to thyrotropin-releasing hormone in endogenous depression. ( Bjørum, N; Kijne, B; Kirkegaard, C; Krog-Meyer, I; Lumholtz, B; Lykke-Olesen, L; Smith, E, 1985)
" Moreover, the endocrine and behavioral deficits of bulbectomized rats are reversed by the chronic administration of drugs that reverse the symptoms of depression in people when given chronically."	1.27	Effects of antidepressant drugs on the behavior of olfactory bulbectomized and sham-operated rats. ( Jesberger, JA; Richardson, JS, 1986)
"To assess prospectively the predictability of therapeutic dosage based on tricyclic antidepressant (TCA) concentrations after a single dose, 30 subjects were given amitriptyline."	1.27	Reliability of amitriptyline dose prediction based on single-dose plasma levels. ( Khazanie, PG; Madakasira, S, 1985)
" Chronic administration of imipramine-HCl (1 and 5 mg/kg, i."	1.27	Effects of antidepressant drugs on a quickly-learned conditioned-suppression response in mice. ( Kameyama, T; Nagasaka, M; Yamada, K, 1985)
" Pharmacokinetic data on benzodiazepines thus in particular are important for design of dose, dose intervals and prediction (warning) about possible accumulation after repeated doses."	1.26	The contribution of pharmacokinetics to the best use of benzodiazepines and antidepressants. ( Gram, LF, 1982)
"Chronic mood disorders were also assessed using RDC criteria."	1.26	Chronic mood disorders in depressed outpatient--diagnosis and response to pharmacotherapy. ( Prusoff, BA; Rounsaville, BJ; Sholomskas, D, 1980)
"The imipramine-treatment group failed to have either earlier response or better final outcome."	1.26	Dexamethasone suppression test and selection of antidepressant medications. ( Albala, AA; Carroll, BJ; Feinberg, M; Gardner, R; Greden, JF; Kronfol, Z; Mukhopadhyay, S, 1981)
" Evaluation of free, instead of total levels did not help to clarify the relationship between clinical and pharmacokinetic variables."	1.26	Antidepressive effect and pharmacokinetics of amitriptyline with consideration of unbound drug and 10-hydroxynortriptyline plasma levels. ( Breyer-Pfaff, U; Brinkschulte, M; Gaertner, HJ; Kreuter, F; Scharek, G; Wiatr, R, 1982)
"Amitriptyline treatment also produced a decrease in peripheral noradrenaline concentration in all subgroups, while an increase was observed with lithium."	1.26	Blood noradrenaline and 5-HT levels in depressed women during amitriptyline or lithium treatment. ( Corona, GL; Cucchi, ML; Fenoglio, L; Frattini, P; Santagostino, G; Savoldi, F; Zerbi, F, 1982)
" Thus, this adverse effect could be avoided by monitoring levels and reducing dosage when appropriate."	1.26	Tricyclic-antidepressant-induced delirium and plasma drug concentration. ( Preskorn, SH; Simpson, S, 1982)
"Some types of bipolar depression may be considered as atypical if accompanied by reversed vegetative change."	1.26	Atypical depression. ( Davidson, JR; Miller, RD; Sullivan, JL; Turnbull, CD, 1982)
"In 34 drug-free patients with primary endogenous depression treated with amitriptyline, the application of EEG-monitored sleep criteria alone was more significant than clinical status alone in the prediction of clinical response."	1.26	Sleep and treatment prediction in endogenous depression. ( Coble, PA; Kupfer, DJ; Neil, JF; Shaw, DH; Spiker, DG; Ulrich, R, 1981)
"Amitriptyline and nortriptyline plasma levels were measured in depressed outpatients 24 hours after a single dose of amitriptyline and following chronic dosing to steady state."	1.26	Prediction of steady-state plasma levels of amitriptyline and nortriptyline from a single dose 24 hr. level in depressed patients. ( Amsterdam, J; Brunswick, DJ; Mendels, J; Rothbart, M; Sandler, K; Schless, A, 1980)

Research

Studies (852)

Authors

Clinical Trials (9)

Trial Overview

Trial Outcomes

Change in Beck Depression Inventory II (BDI-II)

Timeframe	Studies, this research(%)	All Research%
pre-1990	534 (62.68)	18.7374
1990's	257 (30.16)	18.2507
2000's	48 (5.63)	29.6817
2010's	13 (1.53)	24.3611
2020's	0 (0.00)	2.80

Authors	Studies
Sommer, C	1
Alten, R	1
Bär, KJ	1
Bernateck, M	1
Brückle, W	1
Friedel, E	1
Henningsen, P	1
Petzke, F	1
Tölle, T	1
Üçeyler, N	1
Winkelmann, A	1
Häuser, W	1
Tiihonen, J	2
Tanskanen, A	1
Hoti, F	1
Vattulainen, P	1
Taipale, H	1
Mehtälä, J	1
Lähteenvuo, M	1
Revet, A	1
Montastruc, F	1
Raynaud, JP	1
Baricault, B	1
Montastruc, JL	2
Lapeyre-Mestre, M	1
Reyes-Mendez, ME	1
Castro-Sánchez, LA	1
Dagnino-Acosta, A	1
Aguilar-Martínez, I	1
Pérez-Burgos, A	1
Vázquez-Jiménez, C	1
Moreno-Galindo, EG	1
Álvarez-Cervera, FJ	1
Góngora-Alfaro, JL	1
Navarro-Polanco, RA	1
Alamilla, J	1
Gassen, NC	1
Hartmann, J	1
Zschocke, J	1
Stepan, J	1
Hafner, K	1
Zellner, A	1
Kirmeier, T	1
Kollmannsberger, L	1
Wagner, KV	1
Dedic, N	1
Balsevich, G	1
Deussing, JM	1
Kloiber, S	1
Lucae, S	1
Holsboer, F	6
Eder, M	1
Uhr, M	2
Ising, M	2
Schmidt, MV	1
Rein, T	1
Zanier-Gomes, PH	1
de Abreu Silva, TE	1
Zanetti, GC	1
Benati, ÉR	1
Pinheiro, NM	1
Murta, BM	1
Crema, VO	1
Rheker, J	1
Winkler, A	1
Doering, BK	1
Rief, W	1
Sanna, MD	1
Ghelardini, C	2
Galeotti, N	2
Ghaffariyeh, A	1
Chamacham, T	1
Künzel, HE	1
Ackl, N	1
Hatzinger, M	1
Held, K	1
Holsboer-Trachsler, E	2
Kaschka, W	2
Kasper, S	5
Konstantinidis, A	1
Sonntag, A	1
Yassouridis, A	2
Steiger, A	2
Machado, M	1
Lopera, MM	1
Diaz-Rojas, J	1
Jaramillo, LE	1
Einarson, TR	1
Andersohn, F	1
Schade, R	1
Suissa, S	1
Garbe, E	1
Himmerich, H	1
Fulda, S	1
Sheldrick, AJ	1
Plümäkers, B	1
Rink, L	1
Couturier, PL	1
Zahr, N	1
Goldwirt, L	1
Warot, D	1
Allilaire, JF	1
Lambrey, S	1
Moreno-Fernández, AM	1
Cordero, MD	1
Garrido-Maraver, J	1
Alcocer-Gómez, E	1
Casas-Barquero, N	1
Carmona-López, MI	1
Sánchez-Alcázar, JA	1
de Miguel, M	1
Boessen, R	1
Groenwold, RH	1
Knol, MJ	1
Grobbee, DE	1
Roes, KC	2
Adams, JL	1
Almond, ML	1
Ringo, EJ	1
Shangali, WH	1
Sikkema, KJ	1
Gorenstein, C	1
Andrade, L	1
Moreno, RA	1
Artes, R	1
Jain, V	1
Swartz, CM	1
Bartolini, A	1
Curtin, F	1
Redmund, C	1
Diaz, A	1
Fouilloux, C	1
Ortiz, S	1
Berndt, ER	1
Bhattacharjya, A	1
Mishol, DN	1
Arcelus, A	1
Lasky, T	1
Möller, HJ	7
Grunze, H	1
Marcuse, A	1
Schärer, LO	1
Born, C	1
Walden, J	1
Stratz, T	1
Varga, B	1
Müller, W	1
Müller, MJ	2
Dragicevic, A	1
Fric, M	1
Gaertner, I	1
Grasmäder, K	1
Härtter, S	1
Hermann, E	1
Kuss, HJ	2
Laux, G	2
Oehl, W	1
Rao, ML	3
Rollmann, N	1
Weigmann, H	1
Weber-Labonte, M	1
Hiemke, C	1
Caldarone, BJ	1
Karthigeyan, K	1
Harrist, A	1
Hunsberger, JG	1
Wittmack, E	1
King, SL	1
Jatlow, P	3
Picciotto, MR	1
Paykel, ES	8
Scott, J	2
Teasdale, JD	1
Johnson, AL	2
Garland, A	1
Moore, R	1
Jenaway, A	1
Cornwall, PL	1
Hayhurst, H	1
Abbott, R	1
Pope, M	1
Hale, AS	1
ARNOLD, OH	1
FOITL, G	1
FREED, H	1
GROSS, H	1
KALTENBAECK, E	1
DUNLOP, E	1
PRESSMAN, MD	1
WEISS, LB	1
MADALENA, JC	1
NOVAIS FILHO, H	1
MARTINS, JC	1
VAISBERG, M	1
SAUNDERS, JC	1
BOLZANI, L	1
SLIVAR, G	1
BRATLUND, H	1
STROMGREN, LS	2
THALMANN, R	2
OLESEN, TB	1
GREENFIELD, AR	2
HALL, J	1
LONIE, D	1
JORGENSEN, F	1
JEPPESEN, F	1
STROMGREN, E	1
STUART, MH	1
ROSSINI, R	1
BERTUCELLI, L	1
DI PIAZZA, P	1
BROWNE, MW	1
KREEGER, LC	1
KAZAMIAS, NG	1
KRAUSE, G	1
LAI, G	2
JACKSON, D	1
BERNARD, LA	1
BENTLIF, P	1
DECLICH, M	1
MOROSINI, C	1
ROSE, JT	1
LEAHY, MR	1
PLOWMAN, R	1
ERNST, EM	1
JENSEN, E	1
SCHULSINGER, F	2
HORDERN, A	3
HOLT, NF	2
BURT, CG	2
GORDON, WF	2
MASTER, RS	1
VENCOVSKY, E	1
BARCIASALORIO, D	1
ROPERT, R	1
LAIZEROWITCH, L	1
SCHJONSBY, HP	1
WALLING, RG	1
MCLAUGHLIN, BE	1
RYAN, F	1
DRUCKER, T	1
KAMMERER, T	1
GEISSMANN, P	1
BUCHHEIT, F	1
WARTEL, R	1
THONIER, M	1
PETIT, P	1
ROURE, J	1
PRANGE, AJ	2
STORROW, HA	1
MANS, J	1
SENES, M	1
DIPIAZZA, P	1
LEVI-MINZI, S	1
PENNINGTON, VM	1
HOENIG, J	2
ABDOU, FA	1
OHNELL, LK	1
SAINSBURY, MJ	1
AYD, FJ	1
BLACHLY, PH	1
FLEGEL, H	1
SCHMIDT, E	1
SNOW, LH	1
RICKELS, K	6
KLINE, NS	3
HOLLISTER, LE	2
OVERALL, JE	2
JOHNSON, M	1
PENNINGTON, V	1
KATZ, G	1
SHELTON, J	1
VISRAM, S	1
RICHMOND, PW	1
ROBERTS, AH	1
KRIS, EB	1
GERST, D	1
ORNSTEIN, PH	1
FELLNER, CH	1
VERGA, G	1
GILLINGHAM, FJ	1
SMYTHIES, JR	1
KOLLBERG, H	1
COFFEE, HL	1
ENGELMEIER, MP	1
KIND, H	1
ANGST, J	3
LUCAS, AR	1
LOCKETT, HJ	1
GRIMM, F	1
RAVN, J	2
BARDUAGNI, S	1
FERRARI, ML	1
SANDIFER, MG	1
WILSON, IC	1
GAMBILL, JM	1
LEHMANN, HE	1
BOCKNER, S	1
HOCK, CW	1
POLLITT, J	1
JENKINS, LC	1
GRAVES, HB	1
HOVE, H	1
STARK, JE	1
BETHUNE, DW	1
SOULAIRAC, A	1
BARON, JB	1
GEIER, S	1
DE MIJOLLA, A	1
AYMARD, N	1
THANGAPREGASSAM, MJ	1
WHITE, AG	1
JOST, F	1
WEBER, E	1
KROGH, I	1
MATSUMOTO, Y	1
SASAKI, S	1
YAMAGAMI, R	1
ISHIKAWA, T	1
OLTMAN, JE	1
FRIEDMAN, S	1
Suzuki, E	1
Yoshida, Y	1
Shibuya, A	1
Miyaoka, H	2
Gillman, PK	1
Siepmann, M	1
Kirch, W	1
Krause, S	1
Joraschky, P	1
Mueck-Weymann, M	1
Buckley, MJ	1
Surowy, C	1
Meyer, M	1
Curzon, P	1
Deuschle, M	6
Luppa, P	1
Gilles, M	2
Hamann, B	2
Heuser, I	8
SETTEL, E	1
Krumm, B	1
Bindeballe, N	1
Colla, M	3
Lederbogen, F	3
Steimer, W	1
Zöpf, K	1
von Amelunxen, S	1
Pfeiffer, H	1
Bachofer, J	1
Popp, J	1
Messner, B	1
Kissling, W	3
Leucht, S	1
Rosenlicht, NZ	1
Riley-Lazo, KP	1
Sein Anand, J	1
Chodorowski, Z	1
Habrat, B	1
Furukawa, TA	1
Barbui, C	2
Cipriani, A	1
Brambilla, P	1
Watanabe, N	1
Chakrabarti, K	1
Singh, PM	1
Joshi, SP	1
Jardri, R	1
Medjkane, F	1
Cuisset, JM	1
Vallee, L	1
Delion, P	1
Goeb, JL	1
Olgiati, S	1
Calobrisi, A	1
Kiev, A	1
Pfuhlmann, B	1
Gerlach, M	1
Burger, R	1
Gonska, S	1
Unterecker, S	1
Jabs, B	1
Riederer, P	2
Deckert, J	1
Peles, E	1
Schreiber, S	1
Adelson, M	1
Takahashi, H	1
Kamata, M	1
Yoshida, K	1
Higuchi, H	1
Ishigooka, J	1
Hellweg, R	1
Ziegenhorn, A	1
Altintoprak, AE	1
Zorlu, N	1
Coskunol, H	1
Akdeniz, F	1
Kitapcioglu, G	1
Brockington, IF	1
Kendell, RE	1
Wainwright, S	1
Lange, H	1
Burch, JE	3
Hullin, RP	2
Feighner, JP	4
Gram, LF	3
Brinkschulte, M	2
Gaertner, HJ	7
Schied, HW	1
Breyer-Pfaff, U	7
Giedke, H	9
Mahal, A	1
Siris, SG	1
Rifkin, AE	1
Reardon, GT	1
Rush, AJ	4
Roffwarg, HP	3
Giles, DE	3
Schlesser, MA	1
Fairchild, C	1
Tarell, J	1
Jungkunz, G	1
Glen, AI	1
Shepherd, M	1
Escande, M	1
Granier, F	1
Girard, M	1
Edelbroek, PM	5
de Wolff, FA	3
Arató, M	3
Rihmer, Z	2
Szádóczky, E	1
Grof, P	1
Maas, JW	8
Kocsis, JH	6
Bowden, CL	11
Davis, JM	7
Redmond, DE	1
Hanin, I	11
Robins, E	7
Mendlewicz, J	11
Pinder, RM	2
Stulemeijer, SM	2
van Dorth, R	2
Koslow, SH	9
Katz, MM	8
Gibbons, RL	1
Stokes, PE	3
Montgomery, SA	10
Montgomery, DB	4
McAuley, R	3
Rani, SJ	2
Roy, D	3
Georgotas, A	1
Krakowski, M	1
Gershon, S	3
Syvälahti, E	1
Salminen, J	1
Lehtinen, V	1
Kupfer, D	1
Pugh, R	1
Bell, J	1
Cooper, AJ	2
Dunstan, S	1
Greedharry, D	1
Pomeroy, J	1
Raptopoulos, P	1
Rowsell, C	1
Steinert, J	2
Priest, RG	2
Tiplady, B	2
Elton, RA	1
Loudon, JB	2
Møller, SE	4
Honoré, P	2
Larsen, OB	2
Claghorn, J	2
Goldstein, BJ	3
Behrnetz, S	1
Bush, DF	1
Huitfeldt, B	2
Abou-Saleh, MT	4
Coppen, A	5
Larsen, FW	1
Hansen, CE	1
O'Connor, M	1
Grigor, J	1
Shipley, JE	2
Kupfer, DJ	19
Dealy, RS	4
Griffin, SJ	3
Coble, PA	8
McEachran, AB	2
Grochocinski, VJ	1
Berken, GH	1
Weinstein, DO	1
Stern, WC	3
García-Sevilla, JA	1
Zis, AP	2

Trial	Phase	Enrollment	Study Type	Start Date	Status
The Influence of Pharmacotherapy and Psychotherapy for MDD After Remission on Psychology and Neuroimaging：A Comparative Longitudinal Study[NCT01831440]		200 participants (Anticipated)	Interventional	2011-01-31	Recruiting
Rumination Focused Cognitive Behavioral Therapy for Major Depression and Recurrent Depression and Relapse Prevention -a Pragmatic RCT Study in a Danish Psychiatric Outpatient Service[NCT02278224]		131 participants (Actual)	Interventional	2013-11-30	Completed
TeamCare PCN: Collaborative Care for Patients With Diabetes and Depression in Primary Care Networks[NCT01328639]		157 participants (Actual)	Interventional	2010-11-30	Completed
Efficacy and Safety Analyses of Mirtazapine in the Treatment of Malignant Tumor Related Depression: A Phase II, Placebo-controlled, Randomized, Double-blinded Clinical Trial in Advanced Non-small Cell Lung Cancer Patients[NCT02650544]	Phase 2	236 participants (Anticipated)	Interventional	2015-12-31	Active, not recruiting
Vortioxetine Monotherapy for Major Depressive Disorder in Type 2 Diabetes: Role of Inflammation, Kynurenine Pathway, and Structural and Functional Brain Connectivity as Biomarkers[NCT03580967]	Phase 4	0 participants (Actual)	Interventional	2019-07-01	Withdrawn (stopped due to COVID-19 Pandemic interfered with Pt recruitment)
Study of Antidepressants in Parkinson's Disease[NCT00086190]	Phase 3	115 participants (Actual)	Interventional	2005-06-30	Completed
Treatment Strategy to Prevent Mood Disorders Following Traumatic Brain Injury[NCT00704379]	Phase 2/Phase 3	94 participants (Actual)	Interventional	2008-06-30	Completed
[NCT05753943]		0 participants	Expanded Access		No longer available
A Double-Blind, Placebo-Controlled Study of Brexpiprazole in the Treatment of Borderline Personality Disorder.[NCT03418675]	Phase 2	80 participants (Actual)	Interventional	2018-11-26	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Beck Depression Inventory II ranges from 0-63. Higher score indicates more severe depression. 0-13 minimal depression, 14-19 mild depression, 20-28 moderate depression, 29-63 severe depression. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase

Change in Brief Psychiatric Rating Scale (BPRS)

Intervention	Change in BDI-II score (Mean)
Paroxetine	-9.7
Venlafaxine Extended Release	-9.6
Placebo	-5.2

Brief Psychiatric Rating Scale. Maximum score 126. Higher score indicates greater psychiatric difficulties. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase

Change in Geriatric Depression Rating Scale (GDS)

Intervention	Change in BPRS score (Mean)
Paroxetine	-9.0
Venlafaxine Extended Release	-9.8
Placebo	-4.4

Geriatric Depression Scale ranges from 0-30. Higher score indicates more severe depression. 0-9 normal, 10-19 mild depression, 20-30 severe depression. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase

Change in Hamilton Depression Rating Scale (HAM-D) Scores

Intervention	Change in GDS score (Mean)
Paroxetine	-6.9
Venlafaxine Extended Release	-6.9
Placebo	-2.8

Change in Hamilton Rating Scale for Depression over 12 weeks. Hamilton Depression Rating Scale ranges from 0-50. Higher scores represent more significant depression. Mild depression ranges from 8-13, moderate depression from 14-18, severe 19-22 and very severe any score over 23. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase

Change in Montgomery-Asberg Depression Rating Scale (MADRS)

Intervention	Change in HAM-D score (Mean)
Paroxetine	-13.0
Venlafaxine Extended Release	-11.0
Placebo	-6.8

Montgomery-Asberg Depression Rating Scale ranges from 0-60. Higher score indicates more severe depression. 0-6 normal, 7-19 mild depression, 20-34 moderate depression, greater than 34 severe depression. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase

Change in Parkinson's Disease Questionnaire (PDQ) - 39 - Emotional Well-Being

Intervention	Change in MADRS score (Mean)
Paroxetine	-13.6
Venlafaxine Extended Release	-10.9
Placebo	-6.6

Parkinson's Disease Questionnaire (PDQ-39) - Emotional Well-Being maximum score 24, minimum score of 0.Lower score indicates a better perceived health status. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase

Change in Parkinson's Disease Questionnaire (PDQ) - 39 - Overall

Intervention	Change in PDQ-39 Emotional score (Mean)
Paroxetine	-21.4
Venlafaxine Extended Release	-20.7
Placebo	-10.9

Parkinson's Disease Questionnaire (PDQ-39) Total. Range 0-100. Lower score indicates a better perceived health status. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase

Change in Pittsburgh Sleep Quality Index (PSQI)

Intervention	Change in PDQ-39 score (Mean)
Paroxetine	-8.0
Venlafaxine Extended Release	-8.4
Placebo	-5.3

Pittsburgh Sleep Quality Index scores range from 0-21, with higher scores indicating severe sleep difficulties. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase

Change in Short Form 36 Health Survey - Mental Component Summary

Intervention	Change in PQSI score (Mean)
Paroxetine	-2.1
Venlafaxine Extended Release	-2.6
Placebo	-1.1

Short Form 36 Health Survey. Range 0-100. Higher score indicates a better perceived quality of life. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase

Change in Short Form 36 Health Survey - Mental Health

Intervention	Change in SF-36 mental score (Mean)
Paroxetine	11.4
Venlafaxine Extended Release	9.5
Placebo	4.8

Short Form 36 Health Survey - Mental Health subscale ranges from 0-100. Higher score indicates a better perceived quality of life. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase

Change in Short Form 36 Health Survey - Role-Emotional

Intervention	Change in SF-36 Mental Health score (Mean)
Paroxetine	16.7
Venlafaxine Extended Release	17.4
Placebo	9.7

Short Form 36 Health Survey - Emotional subscale ranges from 0-100. Higher score indicates a better perceived quality of life. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase

Change in Short Form 36 Health Survey - Vitality

Intervention	Change in SF-36 Role score (Mean)
Paroxetine	39.5
Venlafaxine Extended Release	26.9
Placebo	12.7

Short Form 36 Health Survey - Vitality subscale ranges from 0-100. Higher score indicates a better perceived quality of life. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase

Change in Snaith Clinical Anxiety Scale (CAS)

Intervention	Change in SF-36 vitality score (Mean)
Paroxetine	13.5
Venlafaxine Extended Release	9.1
Placebo	4.7

Snaith Clinical Anxiety Scale. Range 0-21. Higher scores indicate increased anxiety. Score greater than 8 indicates clinical anxiety. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase

Change in Unified Parkinson's Disease Rating Scale (UPDRS)

Intervention	Change in CAS score (Mean)
Paroxetine	-3.6
Venlafaxine Extended Release	-3.2
Placebo	-2.4

Unified Parkinson's Disease Rating Scale. Higher score indicates more severe Parkinson's disease symptoms. Total maximum = 176. Mental maximum = 52, Activities of Daily Living maximum = 52, Motor maximum = 72. Minimum = 0. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase

Change in Unified Parkinson's Disease Rating Scale (UPDRS) - Bulbar

Intervention	Change in UPDRS score (Mean)
Paroxetine	-8.7
Venlafaxine Extended Release	-7.0
Placebo	-4.3

Unified Parkinson's Disease Rating Scale - Bulbar maximum score 24, minimum score of 0. Higher score indicates more severe Parkinson's disease symptoms. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase

Change in Unified Parkinson's Disease Rating Scale (UPDRS) - Motor

Intervention	Change in UPDRS-Bulbar score (Mean)
Paroxetine	-1.4
Venlafaxine Extended Release	-1.4
Placebo	-0.5

Unified Parkinson's Disease Rating Scale - Motor has a maximum score of 72, minimum score of 0. Higher score indicates more severe Parkinson's disease symptoms. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase

Change in Unified Parkinson's Disease Rating Scale (UPDRS) - Tremor

Intervention	Change in UPDRS-motor score (Mean)
Paroxetine	-4.3
Venlafaxine Extended Release	-2.0
Placebo	-1.0

Unified Parkinson's Disease Rating Scale - Tremor subscale ranges from 0-23. Higher score indicates more severe Parkinson's disease symptoms. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase

Iowa Gambling Task Score

Intervention	Change in UPDRS-tremor score (Mean)
Paroxetine	0.4
Venlafaxine Extended Release	0.5
Placebo	-0.6

The Iowa Gambling Task (IGT) evaluates decision making ability. During IGT subjects have to choose between decks of cards which yield high immediate gain but larger future loss (i.e., long term loss), and decks which yield lower immediate gain but a smaller future loss (i.e., a long term gain). The task consists of four decks of cards: A, B, C, and D. The goal in the task is to maximize profit. Subjects are required to make a series of card selections. The decks A and B are long term loss decks and the decks C and D are long term gain decks. The IGT Score reported is the combination of the raw score for each deck combined in the following way: (C+D) - (A+B). The range for this score is: -100 to 100. Higher values of this score indicate better decision making ability. (NCT00704379)
Timeframe: 6 months after TBI

Memory Function Composite

Intervention	units on a scale (Mean)
Placebo	16.67
Sertraline	-0.77

This outcome measures memory function and is a composite of five standardized scores: Brief Visuospatial Memory Test - Revised, Delayed Recall and California Verbal Learning Test, Short Delay Free Recall Number Correct and Discriminability, and Long Delay Free Recall Number Correct and Discriminability. Standardized scores (i.e., z-scores) for each test of this composite were obtained by subtracting the mean raw score of all participants to the raw score of each participant and dividing the result by the standard deviation of the raw scores of all participants. The composite score was obtained by averaging the z-scores of the four memory tests mentioned previously. Range: -3 to 3. Higher scores represent better memory function. (NCT00704379)
Timeframe: 6 months following traumatic brain injury

Neuroimaging Variables (i.e., Fractional Anisotropy [FA] of Frontal White Matter Such as the Cingulate Gyrus)

Intervention	z-scores (Mean)
Placebo	-0.08
Sertraline	0.07

"FA is a measured obtained from Diffusion Tensor Imaging, an image modality of Magnetic Resonance Imaging (MRI). FA is a unitless index. Range: 0 to 1. FA describes the degree of anisotropy of a diffusion process. A value of zero means that diffusion is unrestricted or equally restricted in all directions. A value of one means that diffusion occurs only along one axis and is fully restricted along all other directions. In the context of this study, FA measures the integrity of the cingulate gyrus white matter. Higher FA values reflect higher integrity of the cingulate gyrus white matter tract. Average FA values for the right and left cingulate gyri were summed.~One aim of this project was to identify predictors of the occurrence of mood disturbances during the first 6 months following TBI. The hypothesis for this aim was that patients who develop a mood or anxiety disorder six months after TBI present at baseline with lower FA of the cingulate gyrus than those who do not." (NCT00704379)
Timeframe: Baseline

Social Functioning Examination Total Score

Intervention	unitless index (Mean)
Patients Who Developped a Mood or Anxiety Disorder	0.91
Patients Who Did Not Developped a Mood or Anxiety Disorder	0.94

The Social Functioning Examination (SFE) is a semi-structured interview that measures social functioning in areas such as interpersonal relationships, work adjustment, use of community resources and satisfaction with living environment. Range: 0 to 1. Higher scores denote lower levels of social functioning. (NCT00704379)
Timeframe: 6 months after TBI

Time to Onset of Diagnostic and Statistical Manual (DSM) IV Defined Mood and Anxiety Disorders Associated With Traumatic Brain Injury (TBI)

Intervention	units on a scale (Mean)
Placebo	0.04
Sertraline	0.04

"Following the DSM-IV (now updated by the DSM-5), depressive disorders associated with TBI are categorized as Mood Disorder Due to Another Medical Condition with subtypes: 1) With major depressive-like episode (if the full criteria for a major depressive episode [MDE] are met) or 2) With depressive features (prominent depressed mood but full criteria for a MDE are not met); and 3) with mixed features (e.g. significant irritability, pressured speech and formal thought disorder).~On the other hand, bipolar and related disorders due to TBI are subdivided in: 1) with manic or hypomanic like episode; 2) with manic features; and 3) with mixed features.~A similar conceptual framework has been used to define Anxiety Disorder due to another Medical Condition, in this case, TBI. According to DSM-IV/DSM-5, such diagnosis can be made when, besides an evident pathophysiological relationship with TBI, panic attacks or generalized anxiety are the prominent features of the clinical presentation." (NCT00704379)
Timeframe: 6 months after TBI

Total Community Integration Questionnaire Scores

Intervention	weeks (Mean)
Placebo	21.4264
Sertraline	15.7833

The Community Integration Questionnaire (CIQ) is intended as a brief, reliable measure of an individual's level of integration into the home and community following traumatic brain injury. Total CIQ scores were used as the outcome measure. Range: 0 to 25. Higher scores indicate higher levels of integration into the home and community following TBI. (NCT00704379)
Timeframe: 6 months after TBI

Hamilton Anxiety Rating Scale (HAM-A)

Intervention	units on a scale (Mean)
Placebo	16.77
Sertraline	17.67

A clinician-administered assessment of anxiety that will be assessed at all study visits (Visit 1-Visit 8). Changes in scores from baseline to final visit will be assessed. Higher scores (up to 56) indicate higher levels of anxiety, with 0 being no symptoms of anxiety. (NCT03418675)
Timeframe: assessed at Visits 1 to 8, change in scores from Visit 1 to Visit 8 (baseline to Week 12) is reported

Hamilton Depression Rating Scale (HAM-D)

Intervention	change in score on a scale (Mean)
Placebo	-2.41
Rexulti	-4.88

A clinician-administered assessment of depression that will be assessed at all study visits (Visits 1-8). Higher total scores indicate higher levels of depression (up to 52), while a score of 0 would indicate no depressive symptoms. (NCT03418675)
Timeframe: Assessed at Visits 1 to 8, change in scores from Visit 1 to Visit 8 (baseline to week 12) is reported

Barratt Impulsiveness Scale (BIS)

Intervention	change in score on a scale (Mean)
Placebo	-2.09
Rexulti	-3.81

A self-report assessment of impulsivity that will be assessed at baseline and visit 8. The BIS is composed of 30 items describing common impulsive or non-impulsive (for reverse scored items) behaviors and preferences. Items are scored on a 4-point scale: (Rarely/Never = 1, Occasionally = 2, Often = 3, Almost Always/Always = 4). These scores are summed to produce an overall impulsivity score ranging from 30 (not impulsive) to 120 (extremely impulsive). (NCT03418675)
Timeframe: Baseline (Visit 1), Week 12 (Visit 8)

Borderline Evaluation of Severity Over Time (BEST)

Intervention	score on a scale (Mean)
	Visit 1	Visit 8
Placebo	76.53	68.13
Rexulti	72.27	70.5

A self rated scale used to measure severity and change. The first 12 items of the scale are on a scale from 1-5, with 5 meaning that the item caused extreme distress, severe difficulties in relationships, and/or kept them from getting things done. The lowest rating (1) means it caused little or no problems. Items 13-15 (positive behaviors) are rated according to frequency. Completed at every visit. (NCT03418675)
Timeframe: Assessed at Visits 1 to 8, change in scores from Visit 1 to Visit 8 (baseline to week 12) is reported

Columbia Suicide Severity Rating Scale (CSSRS)

Intervention	score on a scale (Mean)
	Visit 1	Visit 8
Placebo	40.90	29.15
Rexulti	40.54	23.15

"A self-report scale measuring suicidality. Subjects will complete the scale at all visits. Subjects are asked about suicidal thoughts. If answers are no, rater can proceed to suicidal behavior section where subject is asked about any non-suicidal self injurious behavior. If yes, subject is asked about intensity of ideations. In the event of serious threat to themselves, the subject will be escorted to the emergency room. Total score indicates severity of suicidal ideation and behavior, with lower scores representing lower levels of suicidality and higher scores representing higher levels of suicidality. A score of 0 would reflect no suicidality present, whereas a maximum score of 5 would reflect active suicidal ideation with intent to act." (NCT03418675)
Timeframe: Baseline (Visit 1), Week 12 (Visit 8)

MINI International Neuropsychiatric Interview

Intervention	score on a scale (Mean)
	Visit 1	Visit 8
Placebo	1.15	0.23
Rexulti	0.73	0.08

A short-structured interview that assesses comorbid psychiatric disorders according to the DSM 5 criteria. This assessment will be done during the baseline visit. (NCT03418675)
Timeframe: Baseline (Week 1)

Quality of Life Inventory (QOLI)

Intervention	Participants (Count of Participants)
	Major Depressive Episode (Current)	Major Depressive Episode (Past)	Manic Episode (Current)	Manic Episode (Past)	Hypomanic Episode (Current)	Bipolar I Disorder (Current)	Bipolar I Disorder (Past)	Bipolar II Disorder (Current)	Bipolar II Disorder (Past)	Panic Disorder (Current)	Panic Disorder (Lifetime)	Agoraphobia (Current)	Social Anxiety Disorder (Current)	Obsessive Compulsive Disorder (Current)	Post Traumatic Stress Disorder (Current)	Alcohol Use Disorder (Past 12 months)	Substance Use Disorder (Past 12 months)	Any Psychotic Disorder (Current)	Any Psychotic Disorder (Lifetime)	Major Depressive Disorder with Psychotic Features (Current)	Major Depressive Disorder with Psychotic Features (Past)	Anorexia Nervosa (current)	Bulimia Nervosa (Current)	Binge Eating Disorder (Current)	Generalized Anxiety Disorder (Current)	Antisocial Personality Disorder (Lifetime)	ADHD Combined Type (Current)	ADHD Inattentive Type (Current)	ADHD Hyperactive Type (Current)	Tourette's Syndrome (Lifetime)	Persistent Motor Tic Disorder (Lifetime)	Provisional Vocal Tic Disorder (Lifetime)	Provisional Tic Disorder (Lifetime)	Specific Phobia	Body Dysmorphic Disorder (Current)
Placebo	16	12	2	1	1	0	0	0	0	6	11	7	6	3	9	13	11	0	0	0	0	0	4	2	10	8	2	0	1	0	1	0	0	4	3
Rexulti	18	18	2	3	0	0	0	0	1	6	10	9	9	3	12	8	8	0	1	0	0	1	4	4	15	4	4	1	1	1	1	0	0	1	2

A self-report assessment of patient perceived quality of life that will be assessed at baseline and visit 8. Higher scores indicate a higher quality of life, whereas lower scores indicate a lower quality of life. Participants are asked to rate the importance of each domain on a 3-point scale ranging from 1=not important to 3=very important, and to rate how satisfied they are with that domain on a 6-point scale, ranging from -3=very dissatisfied to +3=very satisfied. In scoring, importance ratings are multiplied by satisfaction ratings to produce weighted satisfaction scores for each of the 16 domains. Weighted satisfaction scores are summed and divided by the number of domains that were rated as important or very important to produce a raw score, which is then converted to a t-score, which provides a proxy measurement for perceived quality of life. T-scores range from very low perceived quality of life (0-36) to high perceived quality of life (58-77). (NCT03418675)
Timeframe: Baseline (Week 1), Week 12 (Visit 8)

Self Report Version of Zanarini Scale

Intervention	score on a scale (Mean)
	Visit 1	Visit 8
Placebo	28.89	30.75
Rexulti	28.70	35.71

A self-report scale assessing Borderline Personality severity that will be assessed at all visits.This scale is assessing severity and change in BPD symptoms. This is a 9-item scale measuring severity of different aspects of Borderline Personality Disorder, with each item rated on a 0-4 scale, 0=no symptoms, 4=severe symptoms. Total scores range from 0-36. (NCT03418675)
Timeframe: Baseline (Visit 1), Week 1 (Visit 2), Week 2 (Visit 3), Week 4 (Visit 4), Week 6 (Visit 5), Week 8 (Visit 6), Week 10 (Visit 7), Week 12 (Visit 8)

Sheehan Disability Scale (SDS)

Intervention	score on a scale (Mean)
	Visit 1	Visit 2	Visit 3	Visit 4	Visit 5	Visit 6	Visit 7	Visit 8
Placebo	18.2	12.8	10.7	10.7	9.7	9.6	8.7	9.3
Rexulti	17.6	10.9	7.9	8.0	7.0	6.6	6.0	5.8

Subjects will complete the SDS at all visits. The change in scores from baseline to study completion will be assessed. The scale itself assesses the level of disability from borderline personality disorder (or target disorder) with higher scores indicating a more debilitating disorder. Scores range from 0-30. (NCT03418675)
Timeframe: Baseline (Visit 1), Week 1 (Visit 2), Week 2 (Visit 3), Week 4 (Visit 4), Week 6 (Visit 5), Week 8 (Visit 6), Week 10 (Visit 7), Week 12 (Visit 8)

Symptom Checklist-90 Revised

Intervention	score on a scale (Mean)
	Visit 1	Visit 2	Visit 3	Visit 4	Visit 5	Visit 6	Visit 7	Visit 8
Placebo	17.3	13.3	11.5	12.4	11.7	11.2	12.0	12.7
Rexulti	15.8	10.7	7.8	7.8	7.0	7.9	6.9	7.7

An instrument that helps evaluate a broad range of psychological problems and symptoms of Borderline Personality Disorder psychopathology. This will be assessed at baseline and visit 8.The 115 items are rated by using a 5-step Likert scale (0=not at all, 4=very strong) and provide a global picture of borderline psychopathology. Global scores of borderline psychopathology are calculated by summing 12 items and range from 0-48. Higher scores indicate more severe symptoms of Borderline Personality Disorder. (NCT03418675)
Timeframe: Baseline, Visit 8 (Week 12)

Zanarini Rating Scale for Borderline Personality Disorder

Intervention	score on a scale (Mean)
	Visit 1	Visit 8
Placebo	26.17	20.25
Rexulti	25.42	14.21

A clinician-administered scale assessing Borderline Personality Scale severity at all study visits. Scores range from 0-36. Higher scores represent worse Borderline Personality Disorder severity, and lower scores represent milder Borderline Personality Disorder severity. (NCT03418675)
Timeframe: Baseline (Visit 1), Week 1 (Visit 2), Week 2 (Visit 3), Week 4 (Visit 4), Week 6 (Visit 5), Week 8 (Visit 6), Week 10 (Visit 7), Week 12 (Visit 8)

Article	Year
[Drug therapy of fibromyalgia syndrome : Updated guidelines 2017 and overview of systematic review articles]. Schmerz (Berlin, Germany), 2017, Volume: 31, Issue:3 Topics: Amitriptyline; Anxiety Disorders; Comorbidity; Depressive Disorder; Duloxetine Hydrochloride; Eviden	2017
Anxiety associated with comorbid depression. The Journal of clinical psychiatry, 2002, Volume: 63 Suppl 14 Topics: Adult; Algorithms; Alprazolam; Amitriptyline; Antidepressive Agents; Anxiety Disorders; Benzodiazepi	2002
THE PHARMACOTHERAPY OF THE DEPRESSIVE SYNDROME. Canadian Medical Association journal, 1965, Apr-10, Volume: 92 Topics: Amitriptyline; Antidepressive Agents; Convulsive Therapy; Depression; Depressive Disorder; Desiprami	1965
THE ANTIDEPRESSANT DRUGS. The New England journal of medicine, 1965, Jun-03, Volume: 272 Topics: Amitriptyline; Antidepressive Agents; Central Nervous System Stimulants; Depression; Depressive Diso	1965
[Use of benzodiazepines in the treatment of depression]. L'Encephale, 1983, Volume: 9, Issue:4 Suppl 2 Topics: Amitriptyline; Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Clinical Trials as Topic; Depres	1983
The role of antidepressants in the treatment of affective disorders. American journal of psychotherapy, 1983, Volume: 37, Issue:4 Topics: Amitriptyline; Antidepressive Agents; Bipolar Disorder; Chronic Disease; Clinical Trials as Topic; C	1983
Muscle-contraction (tension) headache. Psychosomatics, 1983, Volume: 24, Issue:4 Topics: Amitriptyline; Anxiety; Biofeedback, Psychology; Conflict, Psychological; Depressive Disorder; Elect	1983
[EEG patterns in the states of wakefulness and sleep during treatment with tricyclic antidepressive agents (imipramine, amitriptyline)]. Psychiatria polska, 1983, Volume: 17, Issue:1 Topics: Amitriptyline; Cerebral Cortex; Depressive Disorder; Electroencephalography; Humans; Imipramine; Sle	1983
Tryptophan and tyrosine availability: relation to clinical response to antidepressive pharmacotherapy. Advances in biochemical psychopharmacology, 1984, Volume: 39 Topics: Amitriptyline; Antidepressive Agents; Clomipramine; Depressive Disorder; Humans; Imipramine; Lithium	1984
Clinical pharmacology of antidepressant drugs: pharmacogenetics. Advances in biochemical psychopharmacology, 1984, Volume: 39 Topics: Adolescent; Adult; Aged; Amitriptyline; Antidepressive Agents, Tricyclic; Child; Depressive Disorder	1984
Plasma level monitoring of antidepressants: theoretical basis and clinical application. Advances in biochemical psychopharmacology, 1984, Volume: 39 Topics: Amitriptyline; Antidepressive Agents, Tricyclic; Clomipramine; Depressive Disorder; Genetic Variatio	1984
The cardiovascular profile of bupropion. The Journal of clinical psychiatry, 1983, Volume: 44, Issue:5 Pt 2 Topics: Adult; Aged; Amitriptyline; Antidepressive Agents; Blood Pressure; Bupropion; Cardiovascular Disease	1983
Implications of dosing tricyclic antidepressants and benzodiazepines in geriatrics. The Psychiatric clinics of North America, 1984, Volume: 7, Issue:4 Topics: Adipose Tissue; Adult; Aged; Aging; Amitriptyline; Antidepressive Agents, Tricyclic; Anxiety Disorde	1984
Safety of antidepressants. International clinical psychopharmacology, 1995, Volume: 9 Suppl 4 Topics: Amitriptyline; Antidepressive Agents; Antidepressive Agents, Tricyclic; Depressive Disorder; Drug In	1995
Fluvoxamine and tricyclic antidepressants (TCAs): how do the TCAs compare as "new" drugs with established fluvoxamine? International clinical psychopharmacology, 1995, Volume: 9 Suppl 4 Topics: Amitriptyline; Antidepressive Agents, Tricyclic; Binding Sites; Cost-Benefit Analysis; Depressive Di	1995
Fluoxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in older patients with depressive illness. Drugs & aging, 1995, Volume: 6, Issue:1 Topics: Aged; Amitriptyline; Clomipramine; Depressive Disorder; Drug Interactions; Fluoxetine; Humans; Rando	1995
Guidelines for the long-term treatment of depression. The Journal of clinical psychiatry, 1994, Volume: 55 Suppl Topics: Adult; Amitriptyline; Antidepressive Agents; Clinical Trials as Topic; Combined Modality Therapy; De	1994
Tricyclic antidepressant concentrations in plasma: an estimate of their sensitivity and specificity as a predictor of response. Journal of clinical psychopharmacology, 1994, Volume: 14, Issue:4 Topics: Adolescent; Adult; Amitriptyline; Antidepressive Agents, Tricyclic; Clinical Trials as Topic; Depres	1994
Time course of improvement under antidepressant treatment: a survival-analytical approach. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 1993, Volume: 3, Issue:2 Topics: Adolescent; Adult; Aged; Amitriptyline; Analysis of Variance; Antidepressive Agents; Depressive Diso	1993
Psychotropic treatment of chronic fatigue syndrome and related disorders. The Journal of clinical psychiatry, 1993, Volume: 54, Issue:1 Topics: 5-Hydroxytryptophan; Amitriptyline; Antidepressive Agents, Tricyclic; Comorbidity; Depressive Disord	1993
Therapeutic efficacy of antidepressants in agitated anxious depression--a meta-analysis of moclobemide studies. Journal of affective disorders, 1995, Oct-09, Volume: 35, Issue:1-2 Topics: Adult; Aged; Amitriptyline; Antidepressive Agents; Anxiety Disorders; Benzamides; Clinical Trials as	1995
Efficacy in long-term treatment of depression. The Journal of clinical psychiatry, 1996, Volume: 57 Suppl 2 Topics: Amitriptyline; Antidepressive Agents; Antidepressive Agents, Second-Generation; Depressive Disorder;	1996
[Pharmacological treatment of delusional depression]. Minerva psichiatrica, 1996, Volume: 37, Issue:1 Topics: Amitriptyline; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Delusions; Depressive Disorde	1996
Safety of mirtazapine: a review. International clinical psychopharmacology, 1995, Volume: 10 Suppl 4 Topics: Adult; Aged; Amitriptyline; Antidepressive Agents, Tricyclic; Depressive Disorder; Dose-Response Rel	1995
Mirtazapine: clinical advantages in the treatment of depression. Journal of clinical psychopharmacology, 1997, Volume: 17 Suppl 1 Topics: Adult; Aged; Amitriptyline; Antidepressive Agents, Tricyclic; Clinical Trials as Topic; Clomipramine	1997
Pharmacological treatment of severely depressed patients: a meta-analysis comparing efficacy of mirtazapine and amitriptyline. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 1997, Volume: 7, Issue:2 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amitriptyline; Antidepressive Agents, Tricyclic; Depress	1997
Efficacy issues with antidepressants. The Journal of clinical psychiatry, 1997, Volume: 58 Suppl 6 Topics: Absenteeism; Age Factors; Amitriptyline; Antidepressive Agents; Combined Modality Therapy; Controlle	1997
Meta-analysis of randomized, double-blind, placebo-controlled, efficacy and safety studies of mirtazapine versus amitriptyline in major depression. Acta psychiatrica Scandinavica. Supplementum, 1997, Volume: 391 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amitriptyline; Antidepressive Agents, Second-Generation;	1997
A meta-analysis of eight randomized, double-blind, controlled clinical trials of mirtazapine for the treatment of patients with major depression and symptoms of anxiety. The Journal of clinical psychiatry, 1998, Volume: 59, Issue:3 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amitriptyline; Antidepressive Agents, Tricyclic; Depress	1998
The use of anticonvulsants to augment antidepressant medication. The Journal of clinical psychiatry, 1998, Volume: 59 Suppl 5 Topics: Adult; Ambulatory Care; Amitriptyline; Anticonvulsants; Antidepressive Agents; Carbamazepine; Clinic	1998
Cost-effectiveness of mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in austria. European psychiatry : the journal of the Association of European Psychiatrists, 1999, Volume: 14, Issue:4 Topics: Amitriptyline; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Austria;	1999
Amitriptyline v. the rest: still the leading antidepressant after 40 years of randomised controlled trials. The British journal of psychiatry : the journal of mental science, 2001, Volume: 178 Topics: Amitriptyline; Antidepressive Agents, Tricyclic; Data Interpretation, Statistical; Depressive Disord	2001
Does thyroid supplementation accelerate tricyclic antidepressant response? A review and meta-analysis of the literature. The American journal of psychiatry, 2001, Volume: 158, Issue:10 Topics: Amitriptyline; Antidepressive Agents, Tricyclic; Controlled Clinical Trials as Topic; Depressive Dis	2001
The role of plasma concentrations in the use of tricyclic antidepressant drugs. Progress in neuro-psychopharmacology, 1979, Volume: 3, Issue:1-3 Topics: Amitriptyline; Antidepressive Agents, Tricyclic; Depressive Disorder; Dose-Response Relationship, Dr	1979
Efficacy of tianeptine in comparative trials versus reference antidepressants. An overview. The British journal of psychiatry. Supplement, 1992, Issue:15 Topics: Amitriptyline; Antidepressive Agents, Tricyclic; Depressive Disorder; Dose-Response Relationship, Dr	1992
[Blood levels of tricyclic antidepressants and their clinical effectiveness (review of the literature)]. Zhurnal nevropatologii i psikhiatrii imeni S.S. Korsakova (Moscow, Russia : 1952), 1991, Volume: 91, Issue:5 Topics: Amitriptyline; Cardiovascular Diseases; Depressive Disorder; Dose-Response Relationship, Drug; Human	1991
Paroxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. Drugs, 1991, Volume: 41, Issue:2 Topics: Amitriptyline; Animals; Antidepressive Agents; Clomipramine; Depressive Disorder; Drug Evaluation; D	1991
Toleration and safety of sertraline: experience worldwide. International clinical psychopharmacology, 1991, Volume: 6 Suppl 2 Topics: 1-Naphthylamine; Amitriptyline; Antidepressive Agents; Depressive Disorder; Desipramine; Drug Overdo	1991
[Therapeutic effects of tianeptine in patients with depression and anxiety disorders with or without associated alcoholism]. Presse medicale (Paris, France : 1983), 1991, Nov-14, Volume: 20, Issue:37 Topics: Amitriptyline; Antidepressive Agents; Antidepressive Agents, Tricyclic; Anxiety Disorders; Depressiv	1991
Effects of antidepressants on human performance: a review. Journal of clinical psychopharmacology, 1990, Volume: 10, Issue:2 Topics: Age Factors; Amitriptyline; Antidepressive Agents; Depressive Disorder; Doxepin; Humans; Imipramine;	1990
Psychopharmacology of depression in neurologic disorders. The Journal of clinical psychiatry, 1990, Volume: 51 Suppl Topics: Amitriptyline; Antidepressive Agents; Depressive Disorder; Electroconvulsive Therapy; Humans; Nervou	1990
Tryptophan to competing amino acids ratio in depressive disorder: relation to efficacy of antidepressive treatments. Acta psychiatrica Scandinavica. Supplementum, 1985, Volume: 325 Topics: Amino Acids; Amitriptyline; Antidepressive Agents; Brain; Brain Chemistry; Clomipramine; Depressive	1985
Sertraline: a new antidepressant. The Journal of clinical psychiatry, 1988, Volume: 49 Suppl Topics: 1-Naphthylamine; Amitriptyline; Animals; Antidepressive Agents; Clinical Trials as Topic; Depressive	1988
Tricyclic-resistant depression: treatment resistance or inadequate treatment? The Journal of clinical psychiatry, 1985, Volume: 46, Issue:10 Topics: Amitriptyline; Antidepressive Agents, Tricyclic; Depressive Disorder; Desipramine; Dose-Response Rel	1985
A controlled trial of amitriptyline and cianopramine in major depression. Clinical therapeutics, 1985, Volume: 7, Issue:6 Topics: Amitriptyline; Clinical Trials as Topic; Depressive Disorder; Double-Blind Method; Humans; Imipramin	1985

Authors	Studies
Sommer, C	1
Alten, R	1
Bär, KJ	1
Bernateck, M	1
Brückle, W	1
Friedel, E	1
Henningsen, P	1
Petzke, F	1
Tölle, T	1
Üçeyler, N	1
Winkelmann, A	1
Häuser, W	1
Tiihonen, J	2
Tanskanen, A	1
Hoti, F	1
Vattulainen, P	1
Taipale, H	1
Mehtälä, J	1
Lähteenvuo, M	1
Revet, A	1
Montastruc, F	1
Raynaud, JP	1
Baricault, B	1
Montastruc, JL	2
Lapeyre-Mestre, M	1
Reyes-Mendez, ME	1
Castro-Sánchez, LA	1
Dagnino-Acosta, A	1
Aguilar-Martínez, I	1
Pérez-Burgos, A	1
Vázquez-Jiménez, C	1
Moreno-Galindo, EG	1
Álvarez-Cervera, FJ	1
Góngora-Alfaro, JL	1
Navarro-Polanco, RA	1
Alamilla, J	1
Gassen, NC	1
Hartmann, J	1
Zschocke, J	1
Stepan, J	1

amitriptyline and Depression, Endogenous